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Autologous stem cell transplantation 
(ASCT) has an established role as a 
treatment modality for hematological 
malignancies. Stem cells for ASCT 
are almost invariably collected from 
peripheral blood after mobilization 
therapy. Plerixafor, a CXCR4 
antagonist, is the latest addition to 
stem cell mobilization and may be 
used in patients who mobilize poorly 
otherwise. This series of studies 
provides additional information to 
support the use of plerixafor.
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ABSTRACT 
 
Autologous stem cell transplantation (ASCT) has an established role as a treatment 
modality for hematological malignancies. Factors influencing cellular composition of the 
stem cell grafts are poorly understood. In some previous studies, stem cell graft 
composition has been linked with immune recovery and long-term outcome after ASCT. 
Traditionally, a combination of chemotherapy and growth factor or growth factor alone has 
been used for autologous stem cell mobilization. Plerixafor is the latest addition for stem 
cell mobilization, where it has been studied mainly in combination with granulocyte-
colony-stimulating factor (G-CSF). 
The prevalence of poor stem cell mobilization in various diseases was studied in the 
retrospective study. Decision algorithms to guide pre-emptive plerixafor use based on 
blood leukocyte and CD34+ cell kinetics were created. Based on the mobilization kinetics 
observed, it was found that if the white blood cell count is on the rise (>5 x 109/L) and blood 
CD34+ cell count is 10 x 106/L after stem cell mobilization with the combination of 
chemotherapy and G-CSF, the use of plerixafor should be considered. Usefulness of this 
algorithm needs to be validated in a prospective study. 
Next, the effects of plerixafor injection in blood cell composition in chemomobilized 
patients with non-Hodgkin's lymphoma (NHL) were studied. Plerixafor injection given in 
the evening was found to increase CD34+ cell mobilization by five-fold in the following 
morning measurements. Furthermore, also other cell populations such as neutrophils, 
lymphocytes and monocytes were mobilized by plerixafor. 
The effects of plerixafor on stem cell graft cellular composition in NHL patients 
mobilized with chemotherapy and G-CSF was also evaluated. The control group included 
patients mobilized with chemotherapy plus G-CSF. Blood grafts collected after plerixafor 
injection were found to contain more primitive stem cells (CD34+CD133+CD38-) as well as 
more T lymphocytes and NK cells than grafts collected in the control group. The effects of 
plerixafor injection appeared to be similar in myeloma patients. 
The possible effects of plerixafor on hematopoietic recovery and long-term outcomes 
after ASCT were studied in patients with NHL. Patients receiving plerixafor-mobilized 
grafts had similar hematopoietic recovery during the first year following ASCT compared 
to control group patients. Also progression-free and overall survival was equal. 
This series of studies provides additional information to support the use of plerixafor in 
patients who mobilize poorly. The importance of graft cell composition in recovery of 
hematopoietic and immune system and long-term prognosis needs to be evaluated in 
prospective studies with larger patient numbers. 
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TIIVISTELMÄ 
 
Potilaan omilla kantasoluilla tehtävät autologiset kantasolujensiirrot ovat vakiinnuttaneet 
asemansa hematologisten syöpätautien hoidossa. Kantasolusiirteen solukoostumukseen 
vaikuttavat tekijät tunnetaan puutteellisesti. Aiemmissa tutkimuksissa siirteen 
solukoostumus on yhdistetty intensiivihoidosta toipumiseen ja pitkäaikaisennusteeseen. 
Perinteisesti kantasolujen mobilisaatiossa on käytetty solunsalpaajan ja kasvutekijän 
yhdistelmää tai kasvutekijää yksin. Pleriksafori on uusin tulokas kantasolujen 
mobilisaatiossa, jossa sitä on tutkittu pääosin yhdessä kasvutekijän kanssa.  
Retrospektiivisessa tutkimuksessa selvitettiin huonon kantasolumobilisaation yleisyyttä 
eri sairauksissa ja rakennettiin huonosti mobilisoivien potilaiden veren valkosolujen ja 
CD34+ solujen kinetiikan perusteella algoritmeja pre-emptiivisen pleriksaforin käytön 
kriteereiksi. Mobilisaatiokinetiikan perusteella todettiin, että mikäli solunsalpaajalla ja 
kasvutekijällä toteutetun mobilisaation jälkeen veren valkosolumäärän ollessa nousussa (>5 
x 109/L) ja veren CD34+ solujen määrä ollessa 10 x 106/L, olisi syytä harkita pleriksaforin 
käyttöä. Tämän mallin toimivuus on syytä varmistaa etenevässä tutkimuksessa. 
Seuraavaksi tutkittiin pleriksaforin vaikutuksia veren solukoostumukseen 
kemomobilisaation saaneilla non-Hodgkin –lymfoomaa (NHL) sairastavilla. Illalla annetun 
pleriksafori-injektion todettiin lisäävän kantasolujen mobilisaatiota noin viisinkertaisesti 
seuraavan aamun mittauksissa. Lisäksi pleriksafori mobilisoi luuytimestä myös muita 
solupopulaatioita kuten neutrofiileja, lymfosyyttejä ja monosyyttejä. 
Kahdessa osatyössä tutkittiin pleriksaforin vaikutuksia kantasolusolusiirteen 
solukoostumukseen solunsalpaajahoidolla ja kasvutekijällä mobilisoiduilla NHL-potilailla. 
Vertailuryhmänä olivat solunsalpaajaa ja kasvutekijää saaneet potilaat. Pleriksafori-
injektion jälkeen kerätyssä siirteessä todettiin enemmän sekä primitiivisiä kantasoluja 
(CD34+CD133+CD38-) että enemmän T-lymfosyyttejä ja NK-soluja kuin kontrolliryhmässä. 
Pleriksafori-injektion vaikutukset näyttivät olevan samansuuntaisia myeloomaa 
sairastavilta potilailta kerätyissä siirteissä.  
Pleriksaforin mahdollisia vaikutuksia kantasolujensiirron jälkeiseen toipumiseen ja 
pitkäaikaisennusteeseen selvitettiin NHL-potilailla. Pleriksaforilla mobilisoituja siirteitä 
saaneilla todettiin kontrolliryhmän kanssa verrannollinen hematopoieesin toipuminen 
ensimmäisen vuoden aikana kantasolujensiirron jälkeen. Myös tautivapaa- ja 
kokonaiselinaika olivat kontrolliryhmää vastaavat. 
Tutkimussarja antaa lisätietoa pleriksaforin käytön tueksi huonosti mobilisoivilla 
potilailla. Siirteen solukoostumuksen merkitys sekä hematopoieettisen että 
immuunijärjestelmän toipumisen ja pitkäaikaisennusteen kannalta vaatii kuitenkin eteneviä 
tutkimuksia suuremmilla potilasmäärillä. 
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1 Introduction 
Chemotherapy has been used in the treatment of lymphoid malignancies for decades. In some 
patients and disease types, chemotherapy can be curative. However, the efficacy of 
chemotherapy against tumor cells is dose-dependent (Frei and Canellos 1980). Higher doses are 
harmful for healthy tissues (e.g. bone marrow) and side-effects limit the doses used in clinical 
practice. To partially overcome these problems, high-dose therapy (HDT) supported by 
autologous stem cell transplantation (ASCT) is used in some clinical settings. The term ASCT is 
often used to comprise the whole treatment modality. HDT is the treatment, however, and 
ASCT constitutes rescue to ameliorate the consequences of the treatment. 
In 2011, altogether 18,605 first ASCTs were reported to the European Group for Blood and 
Marrow Transplantation (EBMT). The two main indications were plasma cell disorders (PCD) 
[(8586 transplants, 46%; mostly multiple myeloma (MM)] and non-Hodgkin lymphomas (NHL) 
(5646 transplants, 30%; Passweg et al. 2013). In almost all transplants (99%), stem cell grafts 
collected from the peripheral blood were used. A successful stem cell mobilization and 
collection of blood stem cells are thus a prerequisite for ASCT. Depending on definition and 
study population, 5 – 30% of patients are hard to mobilize using traditional approaches (Pusic et 
al. 2008, Jantunen and Kvalheim 2010, Wuchter et al. 2010). 
The only accepted quality parameters for autologous stem cell grafts have been the amount 
of CD34-positive (CD34+) stem cells collected and infused and post-transplant engraftment. 
Higher CD34+ cell doses have been linked to faster engraftment (Tricot et al. 1995, Weaver et al. 
1995, Allan et al. 2002, Stiff et al. 2011) and in some studies also superior outcome post-
transplant in terms of better progression-free survival (PFS) and overall survival (OS) (Blystad 
et al. 2004, O’Shea et al. 2006, Bolwell et al. 2007). Also other cells than CD34+ cells, e.g. various 
lymphocyte subsets, may have an important role in the recovery process after HDT and even 
for long-term survival (Porrata et al. 2004a, Porrata et al. 2004b. Katipamula et al. 2006, 
Schmidmaier et al. 2008, Atta et al. 2009, Jantunen and Fruehauf 2011). In addition, immaturity 
of stem cells may also have some impact on time of engraftment after ASCT (Hénon et al. 1998a, 
Zubair et al. 2006). Methods used to mobilize stem cells have an impact on the graft cell 
composition (Fruehauf and Tricot 2010, Jantunen and Fruehauf 2011) in addition to several 
patient- and disease-related factors. 
Plerixafor, the latest approach in the armamentarium for stem cell mobilization, has been in 
clinical use only for a few years. Earlier studies have shown that it effectively mobilizes CD34+ 
stem cells from the bone marrow into the circulation (Liles et al. 2003, Broxmeier et al. 2005). It 
can be safely combined with growth factors, primarily with granulocyte colony-stimulating 
factor (G-CSF) (Flomenberg et al. 2005) or chemotherapy plus G-CSF (Dugan et al. 2010). In 
addition to use in patients who fail to mobilize stem cells, it can be used pre-emptively in 
patients who mobilize poorly (Jantunen et al. 2011, D'Addio et al. 2011, Jantunen and Lemoli 
2012). In previous studies, mainly safety and efficacy in terms of mobilizing CD34+ cells with 
plerixafor have been investigated. These studies have shown that plerixafor not only mobilizes 
CD34+ cells but may also have impact on other cell populations (Fruehauf et al. 2010, Jantunen 
and Fruehauf 2011). Limited data are available on the pre-emptive use of plerixafor in 
chemomobilized patients in regard to graft composition, engraftment and outcome after HDT.  
This study was performed in order to investigate the effects of plerixafor as a part of stem cell 
mobilization for ASCT. The main focuses were stem cell mobilization efficacy and cellular 
composition of the collected grafts. Studies were initiated by analyzing the incidence of poor 
mobilization in different disease entities. In the same study, an algorithm based on mobilization 
kinetics in chemomobilized patients was developed to guide the use of plerixafor.  
Subsequently, the effects of a single plerixafor injection on the white blood cell types and CD34+ 
cell counts were evaluated. Furthermore, blood graft samples collected from poorly mobilizing 
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patients with NHL or MM who were treated with plerixafor combined with chemomobilization 
or G-CSF mobilization were analyzed. Both CD34+ subclasses and lymphocyte subsets were 
investigated by flow cytometry of the cryopreserved grafts. Follow-up data with early and late 
engraftment and survival after HDT were also obtained in NHL patients mobilized with 
plerixafor in two university hospitals.  
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2 Review of the Literature 
2.1. AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN CLINICAL 
PRACTICE 
2.1.1. Non-Hodgkin lymphomas (NHL) 
Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of NHL, 
accounting for approximately 30% of all new lymphoma cases (Gunnellini et al. 2012). DLBCL is 
usually aggressive by its nature, and is currently treated with immunochemotherapy. The 
majority of the patients can be cured with modern therapy. Most randomized studies from the 
pre-rituximab era have not been able to confirm the superiority of HDT+ASCT consolidation 
after shortened or full-length induction therapy over conventional dose chemotherapy in the 
first-line treatment (Greb et al. 2008), although some controversial results have been published 
(Gianni et al. 1997, Haioun et al. 2000, Milpied et al. 2004). DLBCL is, however, currently the 
most common indication for ASCT among lymphomas (Baldomero et al. 2011), because ASCT 
has been shown to be superior in terms of PFS and OS as salvage therapy in patients with 
relapsed DLBCL (Philip et al. 1995). In spite of a lack of strong evidence, ASCT is also an option 
in patients with poor risk initial features and in those who do not obtain complete remission 
after first-line immunochemotherapy (Ljungman et al. 2010, Jantunen and Sureda 2012).  
Follicular lymphomas (FL) have an indolent course of the disease. The role of ASCT in FL has 
been evaluated in several randomized studies after first-line therapy (Lenz et al. 2004, 
Deconinck et al. 2005, Sebban et al. 2006, Ladetto et al. 2008, Gyan et al. 2009). ASCT has been 
shown to give better PFS, but not OS benefit. The randomized CUP trial showed that ASCT 
provides a survival advantage over conventional chemotherapy in patients with relapsed FL 
(Schouten et al. 2003). Also several nonrandomized studies have shown promising outcome 
after ASCT in patients with relapsed FL (Brice et al. 2000, Rohatiner et al. 2007, Le Gouill et al. 
2011). In addition, ASCT is useful in patients with FL transformed into DLBCL (Foran et al. 
1998, Williams et al. 2001, Montoto et al. 2007, Hamadani et al. 2008, Villa et al. 2013).  
Many peripheral T-cell lymphomas (PTCL) are clinically aggressive, and outcome with 
traditional chemotherapies is generally poor (Jantunen and Sureda 2012).  Due to the rarity and 
heterogenenity of PTCL, the number of clinical studies investigating the role of ASCT in PTCL 
has been limited, and most data consists of from small retrospective series (Rodriguez et al. 
2001, Blystad et al. 2001, Jantunen et al. 2004) or from two phase II prospective studies (Reimer 
et al. 2009, d'Amore et al. 2012). However, it is likely that some PTCL patients may benefit from 
ASCT as a part of first-line therapy (Reimer et al. 2009, d'Amore et al. 2012, Jantunen et al. 
2013a). No randomized studies are currently available to assess the role of ASCT in PTCL. 
Mantle cell lymphoma (MCL) has traditionally had a poor long-term outcome. ASCT was 
initially investigated as a treatment for relapse (Vose 2012). In this setting, long-term event-free 
survival (EFS) was a rare event (Vose et al. 2000). Intensive chemotherapy and front-line ASCT 
has been shown to improve long-term outcome and should be considered for eligible patients 
(Dreyling et al. 2005, Geisler et al. 2008, Geisler et al. 2012, Jantunen and Sureda 2012, Jantunen 
et al. 2012).  
Most ASCT studies in B-cell lymphoproliferative diseases have been performed in the pre-
rituximab era. Therefore results of these studies should be assessed with care, and there is an 
urgent need for new prospective studies (Appelbaum 2008, Jantunen and Sureda 2012). 
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2.1.2. Hodgkin lymphoma (HL) 
The prognosis of Hodgkin lymphoma is usually good, and up to 80 – 90% of the cases can be 
cured with initial chemotherapy with or without radiotherapy without ASCT (von Tresckow 
and Engert 2011). For relapsed disease, the prognosis is not as good. ASCT should be 
considered as standard therapy for these patients (Schmitz et al. 1993, Josting et al. 1998, 
Schmitz et al. 2002, Ansell 2012). In those few patients responding poorly to first-line 
chemotherapy, ASCT may also be considered after second-line salvage chemotherapy (Linch et 
al. 1993, Yuen et al. 1997, Lazarus et al. 1999, Moskowitz et al. 2001, Viviani et al. 2010, Rancea et 
al. 2013). 
2.1.3. Multiple myeloma (MM) 
Multiple myeloma (MM) is a B-cell disorder characterized by proliferation of neoplastic cells of 
the plasma cell phenotype. Two decades ago, treatment of MM consisted of melphalan 
combined with prednisone (Gregory et al. 1992). Recently, new molecules have been developed 
and are now in wide clinical use. Currently, MM represents the most frequent indication for 
ASCT (Passweg et al. 2013), and ASCT has become part of standard therapy in symptomatic 
younger myeloma patients (Bird et al. 2011). 
In some studies ASCT has been shown to improve EFS (Attal et al. 1996, Child et al. 2003, 
Fermand et al. 2005, Sonneveld et al. 2007) and OS (Attal et al. 1996, Child et al. 2003) when 
compared with standard therapy. However, not all studies have been able to confirm these 
observations (Segeren et al. 2003, Barlogie et al. 2006). Two recent meta-analyses showed that 
patients who were treated with a single ASCT had a significant PFS benefit, but not a survival 
advantage over standard chemotherapies (Koreth et al. 2007, Faussner and Dempke 2012). 
Prospective randomized studies are currently ongoing to evaluate the importance of HDT 
relative to the non-transplant approach in MM patients.  
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2.2. MOBILIZATION OF BLOOD STEM CELLS FOR AUTOLOGOUS STEM CELL 
TRANSPLANTATION 
 
Figure 1. Hematopoietic stem cell niche and adhesion molecules.  
SDF-1, stromal cell-derived factor-1; CXCR4, C-X-C chemokine receptor type 4; CD26/DPPIV, dipeptidyl-
peptidase 4; VLA-4, very late antigen 4; VCAM-1, vascular cell adhesion molecule 1. 
2.2.1. Mechanisms of stem cell homing and mobilization 
Hematopoietic stem cells have two main specific characteristics that differentiate these cells 
from mature hematopoietic cells: they have the ability to self-renew and the ability to 
differentiate into all cell lineages of the blood and the immune system (Lymperi et al. 2010). In 
the steady state, the majority of hematopoietic stem cells reside in the bone marrow and their 
activity of proliferation, differentiation and release into the circulation is low (Lapidot and 
Kollet 2010).  
The microenvironment where stem cells are located in the bone marrow is called a “niche” 
(Lymperi et al. 2010). The hematopoietic stem cell niche is a complex combination of different 
cell types and a three-dimensional matrix. Cell populations needed for the formation and 
regulation of the niche include osteoblasts (Mansour et al. 2012), sinusoidal endothelial cells 
(Sugiyama et al. 2006), reticular cells (Nagasawa et al. 2011), adipocytes (Naveiras et al. 2009) 
and mesenchymal stem cells (Méndez-Ferrer et al. 2010). In the niche, stem cells adhere to 
stromal cells with various ligands and receptors (Lymperi et al. 2010). Stromal cell-derived 
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factor (SDF-1 or SDF--X-C ligand 12 (CXCL12) is regarded as the primary factor 
responsible for the retention of stem cells in the bone marrow (Lapidot and Petit 2002, Lapidot 
and Kollet 2010). Other adhesion molecules include C-X-C chemokine receptor type 4 (CXCR4), 
CXCR2 (Pelus et al. 2006), CD26 (Christopherson et al. 2004), CD44 (Zöller 2011), CD62L, very 
late antigen 4 (VLA-4), lymphocyte function-associated antigen-1, CD117 (c-Kit) (Cheng et al. 
2010, Kimura et al. 2011) and Robo4 (Smith-Berdan et al. 2011, Rettig et al. 2012, Goto-Koshino 
et al. 2012). By influencing these adhesion molecules and the microenvironment, stem cells can 
be mobilized from the bone marrow to the circulation. The structure of the stem cell niche is 
illustrated in Fig 1. 
Many adhesion molecules are also essential for the homing of stem cells. Homing is thought 
to be a rapid multistep process. Although many different cell types may home to the bone 
marrow, only stem cells homing into the hematopoietic niches can initiate a permanent 
repopulation (Lapidot et al. 2005). Stem cells may proceed from the circulation to the bone 
marrow by interaction with endothelial CXCR4 and SDF-1 (Lapidot et al. 2010). In addition, 
successful homing requires an activation of dynamic and regulated adhesion machinery 
(Lapidot et al. 2010). 
2.2.2. Mobilization with cytokine(s)  
The most commonly used cytokine for stem cell mobilization is granulocyte colony-stimulating 
factor (G-CSF). The first growth factor for stem cell mobilization came into the clinics in 1990 
(Jansen et al. 2002). Administration of G-CSF creates a proteolytic environment in the bone 
marrow by releasing many different proteases that interact with the adhesion molecules and the 
microenvironment and are therefore capable of mobilizing hematopoietic stem cells to the 
circulation (Motabi and DiPersio 2012). These proteases include e.g. SDF-1/CXCL12, 
metalloproteinase-9 (MMP-9), and cathepsin G (CG) (Heissig et al. 2002, Thomas et al. 2002, 
Lévesque et al. 2003).  
Over the years, G-CSF has become the gold standard for the mobilization regimen because of 
its safety and efficacy (Thomas et al. 2002, Mohty and Ho 2011). The most widely used non-
glycosylated G-CSF is filgrastim (Gertz 2010). Typically filgrastim is used over four consecutive 
days (usually 10 μg/kg/d) and apheresis is started on day 5. G-CSF is continued daily until an 
adequate graft has been collected. Alternatively, either glycosylated G-CSF (e.g. lenograstim) or 
GM-CSF (e.g. molgramostim) can be used for mobilization purposes (Kopf et al. 2006, Bensinger 
et al. 2009, Gertz 2010).  
Pegfilgrastim is a pegylated form of filgrastim and it may also be used. Studies have shown 
that a single dose (usually 6 – 12 mg subcutaneous (SC)) of pegfilgrastim may be as effective as 
daily filgrastim injections in terms of stem cell mobilization (Russell et al. 2008, Kobbe et al. 
2009, Putkonen et al. 2009, Simona et al. 2010). The most common side effects of pegfilgrastim 
are tenderness at the injection site and bone pain. These side effects are usually mild and similar 
to filgrastim.  
In recent years, biosimilars to filgrastim have been introduced. Preliminary observations 
indicate that these can also be used for stem cell mobilization (Lefrère et al. 2011, Andreola et al. 
2012). These biosimilar molecules are less costly than the original filgrastim or pegfilgrastim 
(Lefrère et al. 2011). 
2.2.3. Mobilization with chemotherapy plus granulocyte colony-stimulating factor (G-CSF) 
The mobilization of stem cells from the bone marrow to the circulation and the so-called 
‘rebound effect’ after chemotherapy was originally observed in middle 1970’s by Richmann et al 
(Richmann et al. 1976). The first studies of stem cell mobilization and collection after high-dose 
chemotherapy were published in late 1980’s (To et al. 1990). Cyclophosphamide as a single 
agent (from 1.5 g/m2 to up 7 g/m2) or a disease-specific combination of different drugs combined 
with G-CSF can be used as a mobilization regimen. The term “chemomobilization” refers to the 
use of chemotherapy plus G-CSF.  
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Chemomobilization has both advantages and disadvantages when compared to mobilization 
with G-CSF alone. The main advantage provided by chemomobilization is that it usually 
mobilizes more stem cells and thus fewer apheresis procedures are needed. It may also be 
considered as a treatment course for the underlying malignancy as it can provide tumor 
cytoreduction and in vivo purging (Desikan et al. 1998, Gertz 2010). On the other hand, 
chemomobilization is more toxic than G-CSF alone. Patients may have infections, leading to the 
hospitalization, and blood product transfusions are often needed (Koç et al. 2000, Gertz 2010). 
In addition, mobilization takes a longer time and the optimal time to start apheresis is more 
difficult to predict than mobilization with G-CSF alone (Hicks ML et al. 2007). The toxicity of 
chemotherapy depends on the dose of the drugs. This has been verified e.g. in the studies 
comparing low and intermediate doses of cyclophosphamide in myeloma patients (Jantunen et 
al. 2003a, Petrucci et al. 2003). 
2.2.4. Hard-to-mobilize patients 
Depending on patient and disease characteristics as well as the definitions used, 5-30% of 
patients considered for autologous stem cell collection and transplantation are hard to mobilize. 
These patients are at high risk for a collection failure. A minimum blood graft for the single 
transplantation is commonly determined to include at least 2.0 x 106 CD34+ cells/recipient 
weight (kg). Many risk factors for poor mobilization are known (e.g. age, previous treatments 
and disease), but these do not effectively identify all these patients before mobilization 
(Jantunen et al. 2003b, Kuittinen et al. 2004, Jantunen and Kvalheim 2010, Olivieri et al. 2012).  
If a patient is predicted to be hard to mobilize or even if the patient has failed to mobilize 
enough stem cells, there are some potential options. Different mobilization regimens have 
different potential to mobilize stem cells. Currently, the most effective combination for 
mobilizing stem cells is probably chemomobilization combined to plerixafor. Plerixafor can be 
used in a combination with chemomobilization or with G-CSF alone, and it can be used also in a 
pre-emptive manner (Awan et al. 2012, Jantunen and Lemoli 2012). If mobilization failure is 
imminent then remobilization may be considered. Some patients who fail to mobilize with G-
CSF alone can be remobilized successfully. In these cases, chemomobilization or plerixafor plus 
G-CSF can enhance mobilization further (Pusic et al. 2008, Calandra et al. 2008, Jantunen 2011, 
Jantunen and Lemoli 2012).  
Even if further mobilization attempts fail, bone marrow harvest may be used to collect a 
graft. However, it requires hospitalization, is associated with additional costs, discomfort to the 
patient and it is not available in every transplant center (Jantunen and Kvalheim 2010). In 
addition, use of harvested graft frequently results in delayed engraftment in poor mobilizers 
(Watts et al. 1998). The use of G-CSF-stimulated bone marrow grafts have been shown to be 
associated with faster engraftment (Lemoli et al. 2003, Gawronski et al. 2011). In some cases 
bone marrow graft and peripheral blood graft may be combined to achieve a satisfactory 
engraftment after ASCT (Sinitsyn et al. 2009). Theoretically, allogeneic bone marrow 
transplantation could also be a treatment option in patients who fail to mobilize stem cells for 
ASCT, but not all patients meet the other requirements for the procedure. 
2.2.5. Novel strategies 
In addition to plerixafor, other recently evaluated CXCR4 antagonists are POL6326 (De Nigris et 
al. 2012), AMD3465 (Bodart V et al. 2009, De Clercq 2010), and T-140 (Abraham et al. 2007).  
The next molecule to be evaluated in clinical trials 	


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	
a ligand for 
receptor CXCR2. 
 -induced mobilization seems to be dependent also upon CXCR4 
signaling (Christopher et al. 2009). In a murine model, 
has been shown to mobilize stem 
cells from the bone marrow to the circulation (Pelus et al. 2006, Fukuda et al. 2007). Also 
molecules interacting with VLA-4 have been studied for mobilization purposes (Ramirez et al. 
2009, Rettig et al. 2012). 
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2.3. COLLECTION, ENUMERATION AND PROCESSING OF STEM CELL GRAFTS 
2.3.1. Practical aspects of blood stem cell collection 
An adequate stem cell collection is a necessity for successful ASCT. In the beginning of the 
ASCT era, stem cells were collected by harvesting bone marrow. During the years, bone 
marrow harvesting has been replaced by peripheral blood apheresis and today almost all (99%) 
collections are performed by blood apheresis (Passweg et al. 2013). 
The first continuous-flow apheresis device were developed in the early 1960s (Freireich et al. 
1965, Körbling and Freireich 2011). Stem cell yield collected with these first-generation cell 
separators was low. In addition, patients did not receive any mobilization therapy and the 
amount of stem cells in peripheral blood is known to be low at a steady state. The first 
successful aphereses were performed in the 1970s (McCredie et al. 1971). However, an 
autologous bone marrow harvesting was the primary source of stem cells until mid-1990s when 
it was replaced by blood stem cell apheresis (Körbling and Freireich 2011). Currently, there are 
many different commercial apheresis systems available. These differ from each other in terms of 
technical solutions. Stem cell collection efficacy may vary between apheresis systems, and may 
be altered by the collection program and its settings (Wilke et al. 1999, Heuft et al. 2000, 
Sorensen et al. 2011, Wu et al. 2012). In addition, the best blood apheresis volume is still 
debatable (Abrahamsen et al. 2005, Gašová et al. 2010, Bojanic et al. 2011). In many institutions 
the apheresis volume is 2.5 – 3 times that of the estimated blood volume of the patient per 
session. Larger volume apheresis has also been used (Moog 2008, Zubair et al. 2009, Gertz 2010). 
Large-volume apheresis takes more time, and anticoagulant citrate dextrose has to be replaced 
by heparin. Apheresis-related factors may have an effect on the stem cell graft composition as 
different cell populations may be collected in different proportions (Lin et al. 1995, Katipamula 
et al. 2006, Ikeda et al. 2007). 
Differences between bone marrow harvesting and blood apheresis have been evaluated in 
numerous studies. The apheresis procedure with a prior chemomobilization has been reported 
to cause less anxiety and pain for the patient when compared to marrow harvesting (Auquier et 
al. 1995). Platelet and neutrophil engraftment after ASCT is faster if a blood graft is used instead 
of a marrow graft (Geisler et al. 1998, Vellenga et al. 2001). The collection method used has been 
shown to have an impact on cell composition of the graft in healthy adults (Hassan et al. 1996). 
Engraftment with bone marrow grafts might be more rapid if G-CSF is used for priming before 
marrow collection (Lemoli et al. 2003, Gawronski et al. 2011). Stem cell source does not seem to 
have impact on survival after ASCT (Beyer et al. 1995, Schmitz et al. 1996). Total expenses of 
stem cell collection have been reported to be lower or at least similar when blood apheresis is 
used (Anderlini et al. 1996, Smith et al. 1997, Bredeson et al. 1997, Vellenga et al. 2001). Patients 
who fail to mobilize stem cells or fail to collect adequate peripheral blood stem cell grafts 
should be evaluated for re-mobilization or bone marrow harvest (Rick et al. 2000, Goterris et al. 
2005). 
2.3.2. CD34 cell surface antigen  
The CD34 cell surface antigen is a glycoprotein expressed by vascular endothelial cells and 
hematopoietic stem cells (Fina et al. 1990, Krause et al. 1996). The CD34 antigen belongs to the 
CD34 family of cell-surface transmembrane proteins that also include podocalyxin and 
endoglycan (Kerjaschki et al. 1984, Sassetti et al. 2000, Nielsen and McNagny 2008). The 
function of the CD34 antigen is not thoroughly known. It has been proposed to enhance the 
proliferation, block the differentiation of progenitor cells, and enhance the migration and 
trafficking of hematopoietic cells (Krause et al. 1996, Cheng et al. 1996, Hu et al. 1998, Nielsen 
and McNagny 2008). 
In the steady state, the number of CD34+ cells is less than 0.1 % of all white blood cells (WBC) 
in the peripheral blood. Yet, CD34+ stem cells comprise 1 – 3 % of the bone marrow cells. In the 
clinical laboratory context, the CD34 antigen is most commonly used for the enumeration of 
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blood hematopoietic stem cells. As only stem cells homing into the bone marrow can initiate a 
permanent repopulation, the CD34+ cells have been linked to engraftment and also outcome 
after ASCT (Lapidot et al. 2005, Jantunen and Fruehauf 2011). CD34 may also be used as a part 
of flow cytometric diagnosis and subclassification in patients with acute leukemia (Krause et al. 
1996, Buzzai and Licht 2008). 
2.3.3. Enumeration of blood CD34+ cells and assessment of graft CD34+ cell content  
Precise enumeration of blood stem cells is useful in guiding stem cell apheresis and 
transplantation. The amount of CD34+ stem cells in the graft is routinely measured after the 
collection process. Measurements from patient blood are used to ensure adequate mobilization 
and to optimize the timing of apheresis (Yu et al. 1999, Lefrère et al. 2007). Blood CD34+ (B-
CD34+) counts at the time of apheresis have been shown to correlate well with the CD34+ cell 
content in the apheresis product (Remes et al. 1997, Armitage et al. 1997, Hollingsworth et al. 
1999, Villa et al. 2012). Aphereses are usually started when B-CD34+ is over 20 x 106/l. In some 
patients, aphereses are started with lower B-CD34+ levels. However, in these cases, additional 
collections may be required to achieve a sufficient total collection yield (Jantunen and Kuittinen 
2008). 
 
 
Figure 2. A basic principle of the flow cytometry. 
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Flow cytometric analysis of CD34+ stem cells was first introduced in early 1990s and during 
the years it has established its role as the gold standard (Siena et al. 1991, Keeney et al. 2004). 
The basic principle of flow cytometry is to induce interactions between cells and a laser beam. 
Cells cause the laser beam to scatter and this scattering can be measured. Forward scatter (FSC) 
is proportional to the size of the cell and side scatter (SSC) is proportional to the complexity of 
the cell (Virgo and Gibbs 2012). Additionally, fluorochromes are used to separate various cell 
populations. Fluorochromes are coupled with monoclonal antibodies, and therefore they are 
used when information about antigen structures on the cell surface is needed. Fluorochromes 
are molecules that can be excited to a higher energy level with a laser beam. This excitation 
discharges as a photon, which can be detected and measured. Commonly used fluorescent 
molecules are e.g. fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin-chlorophyll-
protein (PerCP) and allophycocyanin (APC) (Virgo and Gibbs 2012). In clinical practice, 
different fluorochromes are often used as panels. The main features of a flow cytometry device 
are presented Fig 2.  
Guidelines for CD34+ enumeration were first published by the International Society of 
Hematotherapy and Graft Engineering (ISHAGE) in 1996 (Sutherland et al. 1996). In these 
guidelines, determination of CD34+ stem cells is based on the use of light scatter properties and 
two-color immunofluorescence by using CD45 FITC/CD34 PE fluorochromes. CD34 PE 
fluorochrome is recommended because of its brightness in the argon laser-based flow cytometer 
and because it makes possible a quantitative enumeration of CD34+ cells. Furthermore, the 
antibody clone used for CD34 detection should be either from class II or class III (e.g. 8G12 or 
581). A minimum of one hundred CD34+ events and 75000 CD45+ events should be counted 
(Sutherland et al. 1996). 
The original guidelines were based on a two-platform method, where an automated 
hematology analyser is used to measure the total amount of collected leukocytes and the 
proportion of CD34+ stem cells from all leukocytes is determined by flow cytometry. Later on a 
single-platform method was introduced (Keeney et al. 1998). This method is based on either 
volumetric measurements or the use of a known concentration of counting beads in the sample 
(Gratama et al. 1998). In a single-platform ISHAGE method, fluorescent microbeads are used at 
a known concentration. With the observed ratio between the number of flow cytometrically 
counted beads and CD34+ cells, the absolute CD34+ cell count can be calculated (Gratama et al. 
1998). Both two- and single-platform methods have been shown to give equivalent results 
(Chapple et al. 2000, Gajkowska et al. 2006). However, the single-platform method is 
recommended due to a lower variability (Keeney et al. 1998). 
Since flow cytometric analysis is more time-consuming and more expensive than routine 
blood cell analysis, also automated hematology analysers have been investigated for CD34+ 
enumeration. The preliminary results have been promising, but clinical applications have been 
restricted to screening of stem cell mobilization (Letestu et al. 2007, Lefrère et al. 2007, Yang et 
al. 2010). 
2.3.4. Cell viability and cultures 
The viability of the collected stem cells is usually assessed by cell stainings and cultures. 7-
aminoactinomycin D (7-AAD) is a fluorescent derivative of actinomycin D. It can be used to 
exclude dead cells in flow cytometry (Schmid et al. 1994). In addition, 7-AAD can be used to 
distinguish apoptotic cells from dead cells (Zembruski et al. 2012). Also other stainings and 
markers for apoptotic and dead cells have been investigated. These include e.g. trypan blue, 
annexin V and SytoR16 (Schuurhuis et al. 2001, Abrahamsen et al. 2002a).  
CFU-GM assay is often used to ensure the viability and differentiation potential of stem cells. 
This is very important as post-thaw parameters (such as CFU-GM) may be the most relevant for 
evaluating the graft quality (Decot et al. 2012). However, CFU-GM assay methods vary between 
transplant centers. Standardization of the culturing procedure and plating a fixed number of 
CD34+ cells have been proposed in order to improve the reliability and reproducibility 
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(Sheikhzadeh et al. 2001. Dobo et al. 2003, Decot et al. 2012). In addition to the traditional CFU-
GM assay, other culturing methods have also been evaluated for clinical use (Motorin et al. 
2003).  
2.3.5. Laboratory processing of the grafts 
In the autologous setting, the collected grafts must be frozen in order to maintain the stem cells 
viable. As the freezing process may harm the stem cells, a cryoprotectant is routinely used. The 
most commonly used cryoprotectant for stem cell storage is dimethylsulfoxide (DMSO) 
(Windrum et al. 2005). DMSO prevents the formation of ice crystals and disruption of the cell 
membranes (Szmant 1975). DMSO is rather non-toxic to stem cells and also to the patient 
(Branch et al. 1994). However, it has been reported to cause many different adverse effects 
during re-infusion of grafts. The most common side effects include nausea, vomiting and 
abdominal cramps that may be caused by the intravenous infusion of a cold liquid (Zambelli et 
al. 1998). In addition, cardiovascular and respiratory problems and neurological toxicity have 
been reported (Zambelli et al. 1998, Ferrucci et al. 2000, Windrum et al. 2005). Some adverse 
effects in this setting may be due to other factors than DMSO itself (Bojanic et al. 2008). The 
most commonly used concentration of DMSO is 10%, but also other concentrations have been 
studied (Abrahamsen et al. 2002b, Liseth et al. 2005, Windrum et al. 2005, Abbruzzese et al. 
2013). The concentration of DMSO may have an impact on the cellular composition of the graft 
and on the post-thaw viability and the clonogenic potential of stem cells (Akkök et al. 2009, 
Smagur et al. 2012). The amount of DMSO can be reduced by combining alternative 
cryoprotectants (Clarke et al. 2009). 
During the time from collection to re-infusion, stem cell grafts are maintained in the freezer. 
Before freezing, grafts can be diluted to a lower cell concentration. In the most institutions, the 
final cell concentration during the cryopreservation is 1 x 108 to 2 x 108 nucleated cells per 
milliliter (Alencar et al. 2010). Nonetheless, the higher cell concentrations have also been 
reported to be safe (Rowley et al. 1994). Grafts are usually freezed by using an automated and 
controlled rate freezing program (Berz et al. 2007). The freezing program used and the duration 
of the cryopreservation may have an impact on the post-thaw viability of stem cells (Tijssen et 
al. 2008, Liseth et al. 2009, Fernyhough et al. 2013). Stem cell grafts are stored in either the liquid 
or vapor phase of nitrogen (most common) or at –80°C in mechanical freezers (Pamphilon et al. 
2007). To avoid infectious contaminations, storage in the vapor phase has been recommended 
(Tedder et al. 1995).  
The standard method for thawing is to warm grafts in a water bath at 37°C (Katayama et al. 
1997). Use of a dry warming device designed for thawing has resulted in similar results (Röllig 
et al. 2002).  
After cryopreservation and thawing, some transplantation centers wash the stem cell grafts 
before re-infusion in order to reduce the amount of DMSO (Windrum et al. 2005). It has been 
reported that washing reduces the incidence of adverse effects in the autologous setting (Syme 
et al. 2004, Sánchez-Salinas et al. 2012). However, the washing procedure may result in a loss of 
CD34+ cells and requires additional laboratory resources.  
2.4. PLERIXAFOR AS A MOBILIZING AGENT 
2.4.1. Pharmacology and pharmacokinetics 
Plerixafor is a bicyclam molecule with the structure 1,1-[1,4-phenylenebis(methylene)]-bis-
1,4,8,11-tetraazacyclotetradecane (De Clercq E et al. 1994). The initial synthesization process has 
been described in detail by Bridger and colleagues (Bridger et al. 1995). The chemical formula of 
plerixafor is depicted in Fig 3.  
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Figure 3. Chemical structure of plerixafor (previously AMD3100). 
 
The pharmacokinetics of plerixafor have been extensively studied both in healthy adults 
(Hendrix et al. 2000, Lack et al. 2005) and in patients with non-Hodgkin lymphoma (NHL) 
(Stewart et al. 2009), Hodgkin lymphoma (HL) (Cashen et al. 2008) or multiple myeloma (MM) 
(Stewart et al. 2009). The pharmacokinetics was described using a two-compartment model with 
first-order absorption (Lack et al. 2005). Plerixafor exhibits linear kinetics in the 40 - 240 μg/kg 
dose range (Genzyme, summary of product characteristics). The pharmacokinetics of plerixafor 
was similar across clinical studies in healthy subjects who received plerixafor alone and in NHL 
or MM patients who received plerixafor in combination with granulocyte colony-stimulating 
factor (G-CSF) (Genzyme, summary of product characteristics). Some of the first clinical trials 
with plerixafor in humans were performed with intravenous administration (Hendrix et al. 
2004). Currently, the recommended dose of plerixafor is 240 μg/kg body weight by SC injection 
in patients with normal renal function.  
Plerixafor is mainly excreted by the kidneys. In the study of Hendrix et al., the clearance and 
estimated half-life (mean 8.6 hours, range: 8.1 – 11.1 hours) of plerixafor were similar across all 
given doses implying dose independency (Hendrix et al. 2004). However, in the case of renal 
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 the dosage should be reduced (Genzyme, 
summary of product characteristics). Co-administration of plerixafor with drugs that reduce 
renal function or compete for active tubular secretion may increase serum concentrations of 
plerixafor or the co-administered drug. In clinical trials, age or gender have not had any effect 
on plerixafor pharmacokinetics (Genzyme, summary of product characteristics). 
2.4.2. Pharmacodynamics and mechanism of stem cell mobilization 
Many hematopoietic and non-hematopoietic cells express CXCR4 on their surfaces (Nagasawa 
et al. 1998). Plerixafor selectively antagonizes CXCR4 by binding to three acidic residues in the 
main ligand-binding pocket of CXCR4 (Asp171 in transmembrane domain [TM]-IV, Asp262 in 
TM-VI and Glu288 in TM-VII) (Wong et al. 2008). By antagonizing CXCR4, plerixafor inhibits 
binding of stromal cell-derived factor SDF-1/CXCL12 (Fricker et al. 2006). This disruption 
results in a rapid mobilization of stem cells from the bone marrow to the circulation (Broxmeyer 
et al. 2005, Martin et al. 2006). Other stem cell mobilizing agents (e.g. G-CSF) have been 
reported to have same kind of effect (Lévesque et al. 2003). 
Plerixafor is highly selective for CXCR4 and it has only a minor interaction with some other 
similar receptors (e.g. CXCR1-3 or CCR1-9) (Fricker et al. 2006). Binding to CXCR4 is both 
concentration and time dependent and is slowly reversible (Fricker et al. 2006). Some studies 
have suggested that plerixafor is a weak partial agonist (Zhang et al. 2002) while others have 
found no agonist activity on CXCR4 (Fricker et al. 2006).  
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Mobilization of WBC and CD34+ is a dose-dependent phenomenom (Liles et al. 2003, Hübel 
et al. 2004) and occurs typically 6 - 9 hours after SC administration of plerixafor (Liles et al. 
2003, Hübel et al. 2004, Devine et al. 2004). When plerixafor is given with G-CSF (usually given 
in the morning), elevation in the peripheral blood CD34+ count is observed from 4 to 18 hours 
after plerixafor administration with a peak CD34+ count measured between 10 and 14 hours. 
2.4.3. Development of plerixafor and preclinical studies 
In 1992, Erik de Clercq and colleagues reported a newly discovered class of potent and selective 
human immunodeficiency virus (HIV) inhibitors (De Clercq et al. 1992). In their studies, one of 
the tested preparations was found to be quite effective against both HIV-1 and HIV-2. That drug 
was characterized by a bicyclam structure in which two cyclam rings were tethered by a direct 
carbon-carbon linkage. Later on, it was noticed that if the aliphatic bridge was replaced by an 
aromatic bridge, the potency was increased up to 100-fold (De Clercq 2009).  
One of the tested bicyclam compounds with the aromatic bridge was JM2987. It showed 
inhibitory activity against the replication of HIV-1 and HIV-2, but was not toxic to the host cells. 
Actually, JM2987 is almost the same compound as JM3100: JM2987 is octahydrobromide 
dehydrate (a bromide salt) and JM3100 is octahydrochloride dehydrate (a chloride salt) (De 
Clercq et al. 1994). As the two salts were equipotent, all further experiments were performed 
with JM3100 (De Clercq 2009). For further development JM3100 was subsequently transferred 
from Johnson Matthey to AnorMED and the “JM” prefix was replaced by “AMD” (De Clercq 
2009). AMD3100 is now generally known as plerixafor. 
 In the beginning, it was thought that plerixafor mediated its anti-HIV activity via viral 
glycoprotein (gp120) (De Vreese K et al. 1997). However, later studies showed that plerixafor 
interacted with CXCR4, which was the actual mechanism of action (Schols et al. 1997a, Schols et 
al. 1997b, Donzella et al. 1998, Esté et al. 1999, Egberink et al. 1999). 
2.4.4. Clinical studies (Phase I) 
The potential of plerixafor to mobilize stem cells from bone marrow was found in a phase I 
clinical trial. In that trial, forty HIV-infected patients with an HIV ribonucleic acid (RNA) level 
>5000 copies/mL and on stable antiretroviral regimens or off therapy were studied. Plerixafor 
showed no or only minimal antiviral activity, as only one patient had a significant HIV RNA 
reduction and the average change in the viral load in all patients was +0.03 log10 HIV RNA. 
Unexpectedly, a rapid leukocytosis (an estimated maximum effect of 3.4 times compared to the 
baseline) was observed in all patients after infusion of plerixafor (Hendrix et al. 2004).  
This anecdotal finding of leukocytosis was soon assessed more thoroughly (Liles et al. 2003). 
Administration of a single dose of plerixafor caused a dose-dependent leukocytosis in healthy 
subjects. The differential white blood counts showed that the number of neutrophils, 
lymphocytes, monocytes, eosinophils, and basophils all increased (Hübel et al. 2004, Broxmeyer 
et al. 2005). Of note, the amount of CD34+ stem cells increased in the peripheral blood after 
plerixafor injection and a large proportion of mobilized CD34+ cells were c-kit positive 
(Broxmeyer et al. 2005). In addition, there was a significant increase in colony forming unit-
granulocyte/macrophage (CFU-GM), erythroid burst forming units (BFU-E) and colony-forming 
unit-granulocyte, erythrocyte, macrophage, megakaryocyte (CFU-GEMM) in the grafts 
collected after plerixafor (Broxmeyer et al. 2005). These observations finally concluded that 
plerixafor mobilizes pluripotent hematopoietic stem cells from the bone marrow to the 
circulation. 
Later, Liles and colleagues studied the effects of plerixafor (160 μg/kg x 1 on day 5) in 
combination with G-CSF (10 μg/kg/day) on mobilization and collection of CD34+ cells from 
healthy subjects (Liles et al. 2005). They showed that plerixafor could be used in combination 
with G-CSF. The combination of these two drugs resulted in higher CD34+ stem cell yields than 
G-CSF alone (Liles et al. 2005). They also observed that when plerixafor was used the 
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leukapheresis products contained significantly higher numbers of T and B lymphocytes than G-
CSF-mobilized leukapheresis products (Liles et al. 2005). 
In an additional phase Ib study plerixafor was evaluated with G-CSF in patients with 
hematological malignancies (Devine et al. 2004). That study included thirteen patients with 
NHL or MM. The results were quite similar to those observed on healthy subjects (Liles et al. 
2005): plerixafor caused a rapid and statistically significant increase in the total WBC and 
CD34+ counts following a single injection (Devine et al. 2004). 
The safety and possible adverse effects of SC injection of plerixafor were studied in both 
phase I studies mentioned before. Plerixafor had only mild and transient adverse effects when 
used alone or in combination with G-CSF (Liles et al. 2005). The most common side effects 
observed were skin erythema at the injection site, abdominal discomfort and flatulence (Devine 
et al. 2004). 
2.4.5. Clinical studies (Phase II) 
The first phase II study was carried out by Flomenberg et al. (Flomenberg et al. 2005). The 
primary objective of that study was to determine whether patients with MM or NHL mobilized 
more progenitor cells per unit blood volume of apheresis after treatment with plerixafor 
combined with G-CSF compared to G-CSF alone. The secondary objectives included the 
number of apheresis procedures needed and engraftment after HDT (Flomenberg et al. 2005). 
All twenty-five patients were mobilized twice: once with G-CSF only and once with a 
combination of plerixafor and G-CSF, thus allowing each patient to serve as his or her own 
control. The patients had a two week wash-out period between these two mobilization rounds. 
G-CSF mobilization consisted of daily SC morning administration of G-CSF 10 μg/kg of actual 
body weight. Apheresis was initially begun on d 4 of G-CSF administration. Apheresis and G-
CSF were continued daily for up to 4 consecutive daily collections until at least 5 x 106 CD34+ 
cells/kg had been collected, whichever occurred first. The dose of plerixafor was 160 μg/kg for 
the first eight patients and 240 μg/kg for the rest of the patients. The first dose of plerixafor was 
given on d 4 and was administered SC followed 6 hours later by apheresis. Plerixafor, G-CSF, 
and apheresis were continued daily thereafter through day 8 similar to the G-CSF treated 
patients. In every case, more hematopoietic stem cells were collected per day of apheresis after 
plerixafor + G-CSF mobilization than after G-CSF alone, irrespective of which regimen was used 
first. In addition, nine patients failed (36%) to ach$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cells/kg when mobilized with G-CSF alone, but in each of these patients, plerixafor + G-CSF was 
successful in obtaining a sufficient graft. It was concluded that by combining plerixafor with G-
CSF it was possible to avoid a mobilization failure in the case of poor mobilization with G-CSF 
alone. Other potential benefits from the use of plerixafor were a lower number of apheresis 
procedures and a higher number of collected CD34+ stem cells. Neutrophil engraftment after 
ASCT was similar between the groups (Flomenberg et al. 2005).  
In 2007, a study involving eleven refractory or relapsed patients with NHL who were 
mobilized with plerixafor combined to G-CSF was published (Gazitt et al. 2007). In that study, 
adequate collection of the target dose of CD34+ stem cells was achieved in all but one patient 
with two days of collection. The dose of G-CSF was 16 μg/kg/d for four days. In addition, all 
patients were treated with plerixafor (240 μg/kg/d). Both drugs were continued until the 
collection target dose of > 2 x 106 CD34+ cells/kg was achieved. All transplanted patients 
engrafted with a mean of ten and twelve days for neutrophils and platelets, respectively. This 
study also contained a comprehensive flow cytometric analysis performed after plerixafor 
injection. It was shown that plerixafor induced mobilization of certain dendritic cell populations 
(Gazitt et al. 2007). Mobilization of tumor cells was also evaluated but was not observed (Gazitt 
et al. 2007). 
The third phase II study was published by Stiff and colleagues in 2009 (Stiff et al. 2009). Their 
study had some similarities to Flomenberg’s earlier study (e.g. inclusion criteria). Altogether 49 
patients (23 with NHL and 26 with MM) were enrolled. The plerixafor dose was 240 μg/kg/d 
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and it was combined with G-CSF (10 μg/kg/d). Twenty-eight patients (57%) were considered as 
heavily pretreated. Adequate stem cell grafts were collected from 47 of 49 patients (96%) with a 
median stem cell yield of 5.9 x 106 CD34+ cells/kg. After ASCT, the median days to neutrophil 
and platelet engraftment were eleven days and 14.5 days, respectively (Stiff et al. 2009). 
The efficacy of plerixafor and G-CSF in poorly mobilizing patients was further investigated 
in patients with MM by Tricot and colleagues (Tricot et al. 2010). They mobilized twenty 
patients (ten proven poor mobilizers and ten predicted poor mobilizers) with a combination of 
plerixafor and G-CSF. In fifteen patients (75%) at least 2 x 106 CD34+ cells/kg were collected. 
Only one patient (5%) did not achieve a sufficient stem cell graft for transplantation. Among the 
proven poor mobilizers, there was no evidence of tumor cell mobilization. Seventeen patients 
proceeded to transplantation. Pooled cells from other collections were used in eight patients 
(47%). Platelet engraftment occurred at a median of sixteen days and nineteen days for proven 
and predicted poor mobilizers, respectively (Tricot et al. 2010). 
One phase II study investigated the potential of plerixafor in patients with HL (Cashen et al. 
2008). That study included 22 patients with relapsed or refractory HL. These patients were 
treated with G-CSF (10 μg/kg/d) and plerixafor (240 μg/kg) and they were compared to 
historical controls mobilized with G-CSF only. In fifteen patients (68%) at least 5 x 106 CD34+ 
cells/kg were collected and twenty-one patients (95%) achieved the minimum collection target 
of at least 2 x 106 CD34+ cells/kg. The collection yields in days 1-2 of apheresis were significantly 
improved over historical controls. Pharmacokinetics of plerixafor was also assessed and it was 
similar to that previously seen in healthy volunteers (Cashen et al. 2008). 
Results from the US expanded access program have been published by Shaughnessy et al. 
(Shaughnessy et al. 2013). The total number of plerixafor-treated patients was 104 (54 patients 
with MM, 43 with NHL, and 7 with HD). In ninety-seven (93%) patients, 2 x 106 CD34+ cells/kg 
were collected in 1–3 days of apheresis. A total of 92 patients (87%) proceeded to ASCT. All 
these patients had a successful engraftment after ASCT (Shaughnessy et al. 2013).  
The vast majority of phase II studies investigated plerixafor in a combination with G-CSF. 
However, one phase II study investigating the efficacy and the safety of plerixafor in a 
chemomobilization setting was also performed. For the study of Dugan and colleagues forty 
patients were enrolled (14 with NHL, 26 with MM) (Dugan et al. 2010). All patients were treated 
with SC plerixafor 240 μg/kg/d for up to five days after chemotherapy (regimen selection was 
based on disease) plus G-CSF. The addition of plerixafor to a chemomobilization resulted in an 
increase in the peripheral blood CD34+ cells and was well tolerated. After ASCT, the median 
times to neutrophil and platelet engraftment were eleven days and 13 days, respectively. Thirty-
five patients completed 12 months post-transplant follow-up and they all had durable 
engraftment (Dugan et al. 2010). 
2.4.6. Clinical studies (Phase III) 
Subsequently, two phase III studies were performed in the United States and Europe, which 
eventually led to the approval of the drug for clinical use for stem cell mobilization in the 
autologous setting. The first study involved patients with NHL (DiPersio et al. 2009a) and the 
second study patients with MM (DiPersio et al. 2009b). Both studies were multicenter, 
randomized (1:1), double-blind and placebo-controlled, and the study designs were quite 
similar.  
In the first study, patients with NHL (DiPersio et al. 2009a) requiring an autologous 
hematopoietic stem cell transplantation who were in their first or second complete remission 
(CR) or partial remission (PR) were eligible for enrollment. All patients received G-CSF (10 
μg/kg) SC daily for up to 8 days. Beginning on the evening of d 4 and continuing daily for up to 
4 days, the patients received either plerixafor (240 μg/kg) or placebo SC. Aphereses were started 
on d 5, ^
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were collected. The primary end point was the percentage of patients who collected  
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Altogether 298 patients were enrolled in the study. A significantly greater proportion of 
	
 

\=
<*
!|
$^


^

=
<
?
!
`
"6 
CD34+ 	{<


_
		
^	

^ with the placebo group (19.6%). Also ?
@
`

106 CD34+ 	{<
 

_
		
^	

	*		=*
^
 in a greater proportion of 
patients in the plerixafor group (86.7%) compared with the placebo group (47.3%). For all 
patients who underwent apheresis, the median number of CD34+ cells collected was 5.69 × 106 
cells/kg for plerixafor-treated patients and 1.98 × 106 cells/kg for placebo-treated patients. 
Sufficient stem cell yield was not achieved in ten plerixafor-treated (6.8%) and 52 placebo-
treated (36.6%) patients, respectively. These patients entered the rescue protocol. 
Altogether 135 of 150 (90.0%) plerixafor-treated patients underwent ASCT after initial 
mobilization versus 82 of 148 (55.4%) in the control group. Among transplanted patients, 
plerixafor-treated patients received a median of 5.41 × 106 CD34+ cells/kg and placebo-treated 
patients received 3.85 × 106 CD34+ cells/kg. All patients who received transplantation in had 
successful neutrophil engraftment and 98% had successful platelet engraftment. The median 
time to engraftment was 10 days for neutrophils and 20 days for platelets in both groups. For 
patients who had undergone transplantation after an initial mobilization (135 in plerixafor 
group and 82 in placebo group), survival at 12 months follow-up visit was similar (88.1% in the 
plerixafor group and 86.6% in the placebo group). 
In the study of patients with MM (DiPersio et al. 2009b), 302 patients were enrolled. A 
significantly greater proportion of patients in the plerixafor group yielded ? 6 × 106 CD34+ 
cells/kg with 
2 apheresis than in the placebo group (71.6% vs. 34.4%). The median number of 
apheresis days required to collect that amount of stem cells was one day in the plerixafor group 
compared with four days in the placebo group. The engraftment after ASCT was similar 
between the groups. 
In both studies, the most commonly observed adverse effects of plerixafor were injection site 
erythema and gastrointestinal disorders. Most of the adverse events were mild or moderate and 
only a few adverse events leading to discontinuation were seen (DiPersio et al. 2009a, DiPersio 
et al. 2009b). 
Both studies included a rescue protocol for patients mobilizing poorly. The results of this 
patient population in the NHL study were published by Micallef et al. (Micallef et al. 2009). 
Altogether 62 patients were enrolled and in 37 of them (59.7%) at least 2.0 × 106 CD34+ cells/kg 
were collected after mobilization with G-CSF plus plerixafor. Fifty-two patients (83.8%) were 
subsequently transplanted. After ASCT, all patients had neutrophil engraftment and in 
addition, all but two patients had also sustained platelet engraftment. 
Furthermore, a subset analysis of the Phase III trial with MM patients showed that plerixafor 
caused mobilization of stem cells that was not dependent on a prior  
B-CD34+ cell count, and the total yield of CD34+ cells from apheresis was significantly higher in 
the plerixafor group than in the placebo group (Nademanee et al. 2012). 
2.4.7. Use of plerixafor in patients mobilizing poorly 
The first larger study with plerixafor in patients who were proven to mobilize poorly was 
performed by Calandra et al. (Calandra et al. 2008). Altogether 115 patients with NHL, MM or 
HL who had failed to mobilize a minimum graft were enrolled in that study. Patients were 
mobilized with G-CSF followed by plerixafor. Plerixafor was started on day 4 and was 
continued daily as well as G-CSF until an adequate graft was obtained. More than 2.0 x 106 
CD34+ cells/kg were collected in 77 patients (66%). When combined with previous collections, 
altogether 87 patients (76%) were eligible to proceed to transplantation. The engratment data 
was available for 36 patients (41%). Thirty-four of these patients (94%) had a durable 
engraftment and were alive at least up to 12 months (Calandra et al. 2008). 
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The compassionate use program (CUP) for plerixafor opened in July 2008 in Europe. It was 
allocated for patients with NHL, HL or MM who had experienced a mobilization failure and 
were not suitable for registration trials (Duarte et al. 2011). The first published data from the 
European CUP was based on a series of 56 patients (24 patients with NHL and 32 patients with 
myeloma) (Duarte et al. 2011). Altogether, there were 73 prior mobilization failures among 
these patients. In that trial, patients were mobilized with G-CSF (10 μg/kg/d) and plerixafor (240 
μg/kg). The first plerixafor injection was given in the evening of the fourth day. G-CSF and 
plerixafor injections were continued daily until 2.0 x 106 CD34+ cells/kg were collected or 
mobilization failure was obvious. After mobilization therapy, 42 of 52 (75%) of patients were 
successfully collected with at least 2.0 x 106 CD34+ cells/kg. Thirty-five out of 56 patients (63%) 
had been transplanted by the time of analysis. All patients had both neutrophil and platelet 
engraftment after ASCT. 
More extensive experience in the European CUP trial was subsequently published by Hübel 
and colleagues (Hübel et al. 2012). It contained altogether 580 patients (270 patients with NHL, 
54 patients with HL and 256 patients with MM). The mobilization process was similar to the 
original CUP study. The median stem cell yield was 3.1 x 106 CD34+ cells/kg and the collection 
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yield was significantly higher in patients with MM than in patients with NHL. No post-ASCT 
analysis was included. In the substudy of the German CUP, poorly mobilizing patients 
mobilized with chemotherapy and/or G-CSF and plerixafor were studied (Hübel et al. 2011). 
The series included 60 patients (28 patients with NHL, 17 patients with MM and 15 patients 
with other malignancies).  The median total stem cell yield was 2.2 x 106 CD34+ cells/kg among 
patients with NHL. All transplanted patients had durable engraftment after ASCT. Additional 
subanalysis and reports based on the CUP trial patients have been published (Fowler et al. 2009, 
Selleslag et al. 2011, Basak et al. 2011). These studies have confirmed that plerixafor can be used 
in addition to G-CSF or also with chemotherapy and mobilizes significantly more CD34+ stem 
cells when compared to the traditional approaches, even in patients with a prior mobilization 
failure.  
Only a few studies about long-term engraftment or outcome are available in this setting. 
Moreb et al. reported outcomes of nine lymphoma and eight MM patients that were treated 
with G-CSF mobilization and received plerixafor as a rescue mobilization in the CUP. In their 
study, long-term engraftment and hospital course were similar between poorly mobilizing 
patients and the control group. Due to the retrospective nature and small number of patients, 
no comparison between groups in outcomes was performed (Moreb et al. 2011). Engraftment 
after ASCT has been reported to be slightly delayed in patients who have been mobilized with 
G-CSF and who have received plerixafor due to inadequate mobilization when compared to 
standard mobilizers (Alexander et al. 2011). 
2.4.8. Pre-emptive use of plerixafor  
The possible utility of plerixafor has been studied also in a pre-emptive setting. In this context, 
the term pre-emptive means that plerixafor is given only if it becomes apparent that stem cell 
mobilization will be inadequate with traditional methods (chemotherapy and/or G-CSF). This 
approach may be beneficial in terms of cost-effective use of plerixafor (Jantunen 2011). Other 
terms used in this setting are just-in-time, add-on, rescue and salvage use. 
Pre-emptive use of plerixafor has been primarily studied in a few small studies among 
patients with NHL or MM (Jantunen et al. 2011, D'Addio et al. 2011, Gopal et al. 2012, Horwitz 
et al. 2011). The retrospective study of Jantunen et al. (Jantunen et al. 2011) included altogether 
63 patients (32 patients with NHL, 29 patients with MM and 2 patients with HL). All patients 
were mobilized with chemotherapy plus G-CSF. In addition, plerixafor was given to 16 patients 
(25%) due to poor stem cell mobilization or due to insufficient stem cell yield of the prior 
aphereses. The median increase in blood CD34+ count was five-fold after the first plerixafor 
injection. Thirteen out of sixteen patients (80%) obtained at least 2.0 x 106 CD34+ cells/kg. All 
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these patients proceeded to ASCT, and all but one patient had neutrophil and platelet 
engraftment. The results from the study of D'Addio were similar, but the minimum collection 
target was achieved in all patients (D'Addio et al. 2011).  
In the study by Alexander et al., altogether 96 MM and NHL patients were retrospectively 
analyzed. Patients were mobilized with cyclophosphamide plus G-CSF and GM-CSF or G-CSF 
alone. In addition, 32 patients mobilized with G-CSF received plerixafor due to inadequate 
mobilization. The investigators reported that neutrophil and platelet engraftment was 
significantly slower in the group of plerixafor-mobilized patients when compared to other 
groups. However, there was no significant difference in WBC count, absolute neutrophil count, 
or platelet count among groups at d +100. No comparisons between groups in regard to long-
term engraftment or outcomes were performed (Alexander et al. 2011). 
In clinical practice, it may be hard to identify in advance patients who mobilize poorly and 
require plerixafor. Therefore, various algorithms to help this identification have been developed 
(Costa et al. 2011, Chen et al. 2012, Sinha et al. 2011, Ozsan et al. 2012, Sancho et al. 2012, 
Abhyankar et al. 2012, Micallef et al. 2013, Milone et al. 2013, Abusin et al. 2013, Hay et al. 2013). 
These algorithms are usually based on predictive factors that are patient dependent, including 
blood CD34+ cell counts, blood WBC counts or stem cell yields. Most of the algorithms are based 
on G-CSF mobilization and only a few algorithms for chemomobilization have been published. 
None of the published algorithms have been accepted widely for clinical use. While different 
transplant centers have their own distinctive mobilization methods, guidelines and practices, it 
has been suggested that each center should determine their own trigger or cut-off levels (To et 
al. 2011). A summary of published algorithms to guide pre-emptive use of plerixafor is 
presented in Table 1. 
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Table 1. Summary of published algorithms to guide pre-emptive use of plerixafor. 
 
Study 
Number of 
included 
patients 
Diseases Mobilization  
method 
Suggested trigger/cut-off level 
for plerixafor 
Costa et al. 2011 50 lymphomas, 
MM 
G-CSF alone Calculated individually on d4 based 
on B-CD34+ count and collection 
target 
Chen et al. 2012 49 lymphomas, 
MM 
G-CSF alone B-CD34+ 5 – 15 x 106/L on d4  
Sinha et al. 2011 1556 lymphomas, 
PCD 
G-CSF alone B-CD34+ <6 x 106/L on d4 or  
B-CD34+ <10 x 106/L on d5 or first 
collection yield <1.0 x 106 CD34 
cells/kg 
Abusin et al. 
2013. 
130 lymphomas, 
PCD 
G-CSF alone B-CD34+ 6/L on d4 
Abhyankar et al. 
2012. 
159 lymphomas, 
PCD, solid 
tumors 
G-CSF alone B-CD34+ <10 x 106/L on d5 (target 
	6 CD34 cells/kg) or  
B-CD34+ >10 x 106/L but <20 x 
106/L on d5 (

		6 CD34 
cells/kg) or first collection yield is 
less than one-half of the desired 
dose 
Sancho et al. 
2012. 
397 lymphomas, 
MM, acute 
myeloid 
leukemia and 
other 
G-CSF alone (mainly) 
or chemotherapy +  
G-CSF 
A peak value of B-CD34+  
	
6/L 
 
Micallef et al. 
2013. 
592 lymphomas, 
PCD 
G-CSF alone (mainly) 
or chemotherapy +  
G-CSF 
Algorithm I:   
B-CD34+ <10 x 106/L on d4 or d5 or 
any collection yield <0.5 x 106 CD34 
cells/kg 
 
Algorithm II:   
B-CD34+ <10 x 106/L for single 
transplantation and <20 x 106/L for 
multiple transplantations on d4 or 
first collection yield <1.5 x 106 CD34 
cells/kg or any collection yield <0.5 
x 106 CD34 cells/kg 
Milone et al. 
2013. 
233 lymphomas, 
MM 
cyclophosphamide  
4 g/m2 + G-CSF 
B-CD34+ <6 x 106/L on d12 or  
B-CD34+ <10 x 106/L on d13 
Ozsan et al. 
2012. 
396 MM cyclophosphamide  
3 g/m2 + G-CSF 
B-CD34+ <10 x 106/L on d13 or  
1 d after WBC>1 
Hay et al. 2013. 354 lymphomas, 
MM, acute 
myeloid 
leukemia and 
other 
chemotherapy +  
G-CSF 
A peak value of B-CD34+  
<16.5 x 106/L 
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2.4.9. Potential concerns regarding plerixafor use 
As discussed earlier, plerixafor is well tolerated and severe adverse effects are seen rarely. 
There are not much data or studies with long follow-up concerning long-term effects. In larger 
studies, the follow-up period has usually been up to 12 months. This is enough to assess 
engraftment, but not enough to assess possible effects of plerixafor regarding patient survival. 
Of note, a higher incidence of therapy-related myelodysplastic syndrome/acute myeloid 
leukemia after ASCT has been reported in patients with plerixafor mobilized stem cells (Deol et 
al. 2013). 
One of the concerns with a mobilizing agent is the potential for tumor cell mobilization. Yet, 
the relevance of graft tumor cell contamination is still debatable (DiPersio et al. 2011). One 
study assessed tumor cell mobilization in myeloma patients, and it seemed that the combination 
of G-CSF plus plerixafor did not increase mobilization of clonal tumor cells compared to G-CSF 
only mobilization (Fruehauf et al. 2010). A similar result has been reported for NHL patients too 
(DiPersio et al. 2009). No data are available in this regard for plerixafor combined with 
chemomobilization in lymphoma patients. In addition, plerixafor not only mobilizes stem cells, 
but also other cell populations are mobilized from the bone marrow to the circulation (Liles et 
al. 2003). These mobilized cells may be collected during the apheresis procedures. This may lead 
to a lower ratio of CD34+ cells and result in greater storage costs (Tanhehco et al. 2010). 
In September 2013, the official price of one 24 mg plerixafor dose in Finland was 7786.82 €. 
As some patients require multiple doses, the total costs of plerixafor alone can rise to substantial 
levels. Few studies in regard of costs and resource utilization have been published. The study of 
Shaughnessy et al. (Shaughnessy et al. 2011), compared retrospectively total costs between 
patients mobilized with G-CSF plus plerixafor with those mobilized with cyclophosphamide 
plus G-CSF. Their conclusion was that there was no difference in median total costs but 
mobilization was more predictable in the plerixafor plus G-CSF group. The use of plerixafor in 
pre-emptive settings has resulted in similar or lower total costs when compared to traditional 
mobilization methods (Li et al. 2011, Vishnu et al. 2012, Kymes et al. 2012, Perkins et al. 2012). 
However, all pharmacoeconomic studies of plerixafor are subject to a number of limitations, 
and this should be taken into consideration before making any final conclusions (Keating 2011). 
No pharmacoeconomic evaluations have been published from the European transplant centers. 
2.5. CELLULAR COMPOSITION OF GRAFTS IN AUTOLOGOUS STEM CELL 
TRANSPLANTATION 
2.5.1. Factors influencing graft cellular composition 
All mobilizing agents have a different and unique potential to mobilize stem cells. Due to the 
complexity of stem cell mobilization, the mobilization methods used may have a variable effect 
on the cellular composition of the graft (Talmadge et al. 1996, Webb et al. 1996, Cesana et al. 
1998, Menéndez et al. 2002, Fruehauf et al. 2010, Jantunen and Fruehauf 2011). Mobilization 
therapy also mobilizes cell populations other than CD34+ cells and may have an impact on the 
maturity stage of mobilized CD34+ stem cells. The other cell populations may have importance 
in terms of engraftment and long-term outcome, and will be discussed in detail later. In 
addition to the mobilization therapy used, there may also be other factors influencing the graft 
cell composition (patient, disease and treatment-related factors). Effects of various mobilization 
methods on cellular composition of autografts are summarized in Table 2. Potential effects of 
graft characteristics in ASCT are presented in Table 3. 
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Table 2. Effect of mobilization regimen on autologous graft content (modified from Jantunen and 
Fruehauf 2011). 
 
Parameter G-CSF alone Chemotherapy  
+ G-CSF 
Plerixafor  
+ G-CSF 
 
CD34+  More than G-CSF alone 
(Narayanasami et al. 2001) 
More than G-CSF alone 
(DiPersio et al. 2009a, DiPersio 
et al. 2009b) 
 
CD34+ 	- More than chemotherapy 
+ G-CSF (Möhle et al. 
1994) 
 More than chemotherapy  
+ G-CSF (Fruehauf et al. 2009) 
 
Lymphocytes More than chemotherapy 
+ G-CSF (Hiwase et al. 
 
 More than G-CSF alone (Holtan 
et al. 2007) 
 
CD3+, CD4+, 
+ 
  More than G-CSF alone (Holtan 
et al. 2007) 
 
Natural killer 
cells 
  More than G-CSF alone (Holtan 
et al. 2007) 
 
Dendritic cells More than chemotherapy 
+ G-CSF (Bolwell et al. 
2003) 
 More than G-CSF alone (Gazitt 
et al. 2007) 
 
2.5.2. CD34+ stem cells and subclasses 
The amount of CD34+ stem cells has been the most important characteristic of an autologous 
stem cell graft in the past, and it is still the only widely accepted indicator for graft quality in 
addition to engrafment after HDT (Jantunen and Fruehauf 2011). The CD34+ cell dose has been 
linked to engraftment and also outcome after ASCT. The CD34+ cell population can be divided 
into subclasses by their antigen properties. Cells of these different subclasses differ from each 
other in terms of their maturity stage, function and repopulating capacity (Terstappen et al. 
1991, Huang et al. 1994, Waller et al. 1995, Larochelle et al. 1996, Beksac and Preffer 2012). 
Higher infused CD34+ cell doses have been shown to result in faster neutrophil and platelet 
engraftment after HDT (Tricot et al. 1995, Weaver et al. 1995, Allan et al. 2002, Stiff et al. 2011). 
In addition, patients receiving higher CD34+ doses need fewer blood product transfusions and 
less supportive care (Ketterer et al. 1998, Schulman et al. 1999, Limat et al. 2000, Klaus et al. 
2007, Stiff et al. 2011).  
The relationship between CD34+ dose and outcome has been studied extensively. Most of the 
published studies have confirmed that larger CD34+ doses are associated with better PFS and 
OS after ASCT (Blystad et al. 2004, Pavone et al. 2006, O’Shea et al. 2006, Bolwell et al. 2007). 
However, not all studies have been able to confirm these observations (Stockerl-Goldstein et al. 
2000, Wang et al. 2007). Reasons why the CD34+ dose and outcome may be linked are not 
known. 
The minimum graft for a single autologous transplantation is usually considered to be at 
least 2.0 x 106 CD34+ cells/kg, which usually means CD34+ cell content measured after collection 
but before freezing. If a tandem (or double) transplantation is an option, then the minimum 
graft is usually at least 4.0 x 106 CD34+ cells/kg divided in two doses. Higher CD34+ doses (e.g. 
4.0 – 8.0 x 106 CD34+ cells/kg for a single transplant and 8.0 – 10.0 x 106 CD34+ cells/kg for a 
tandem transplant) have also been suggested (Siena et al. 2000, Giralt et al. 2009). However, in 
regard to total costs of ASCT and the outcome after ASCT, the optimal CD34+ cell dose still 
remains to be defined. 
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Despite stem cell properties, most CD34+ cells have already been committed to a specific 
lineage (e.g. erythroid, lymphoid, or monomyeloid) (Andrews et al. 1989). In the study of 
Terstappen et al. (Terstappen et al. 1991) CD38 was the most promising marker indicating 
multilineage commitment of CD34+ bone marrow cells. In that study the amount of CD34+ cells 
lacking CD38 antigen (CD34+CD38-) was very low (only 1% of all CD34+ cells), and morphologic 
examination showed that these cells were a homogeneous population of primitive blasts. The 
ability to form colonies was inversely proportionate to CD38 antigen density. In addition, these 
primitive stem cells have been shown to have high self-renewal potential and to be progenitors 
of different cell types (i.e. lymphoid and myeloid) (Huang et al. 1994, Rusten et al. 1994, Miller 
et al. 1999). In ASCT recipients, the amount of infused CD34+CD38- cells has been shown to 
correlate with short-term engraftment but not with long-term hematopoietic reconstitution 
(Zubair et al. 2006). Yet, other studies have reported that some primitive CD34+ cell subtypes 
may also correlate with long-term engraftment (Hénon et al. 1998a, Hénon et al. 1998b, Lanza et 
al. 2001, Ninan et al. 2007). Primitive stem cells may also be more resistant to damage during 
cryopreservation (Ojeda-Uribe et al. 2004). Thrombopoietin has been shown to promote 
survival and stimulate growth of CD34+CD38- cells (Borge et al. 1997, Ramsfjell et al. 1997). 
CD110 is a receptor for thrombopoetin expressed in a subpopulation of CD34+ cells (Ramsfjell et 
al. 1997). The number of CD34+CD110+ cells in the graft has been linked with platelet 
engraftment (Sartor et al. 2007, Wallington-Beddoe et al. 2009).  
Like the CD38 antigen, the CD133 antigen has also been linked with primitiveness of stem 
cells (Yin et al. 1997, Pasino et al. 2000, Hess et al. 2006). In a murine model, use of CD34+CD133+ 
cells has been shown to result in superior engraftment when compared to use of the 
CD34+CD133- cell population (de Wynter et al. 1998, Gordon et al. 2003). In MM patients, the 
higher number of transplanted CD34+CD133+ stem cells has been correlated with better 
neutrophil and platelet recovery after high-dose therapy (Hicks C et al. 2007, Camacho et al. 
2012). Also the expression of CXCR4 on stem cells may have an impact on platelet recovery 
(Hicks et al. 2011).  
The mobilization therapy has an effect on the amount and primitiveness of stem cells in the 
autologous stem cell grafts. Currently, perhaps the most efficient mobilization method in 
clinical use is chemotherapy + G-CSF combined with plerixafor (Dugan et al. 2010, Jantunen and 
Fruehauf 2011). The combination of G-CSF and plerixafor has been shown to mobilize more 
primitive stem cells than G-CSF alone in patients with MM or NHL (Fruehauf et al. 2009, 
Taubert et al. 2011). Mobilization with G-CSF alone has resulted in a higher number of more 
primitive stem cells (CD34+CD38-) when compared to chemotherapy + G-CSF mobilization 
(Möhle et al. 1994). 
2.5.3. Lymphocytes 
All lymphocytes originate from the common lymphoid progenitors (CLP). There are at least 
four major types of lymphocytes: B cells, T cells, natural killer (NK) and NKT cells with features 
of both T cells and NK cells. Lymphocytes are a backbone of the humoral and cell-mediated 
immunity. 
In the context of ASCT, lymphocytes in the graft have been primarily linked with 
engraftment and outcome. It has been shown that the amount of infused lymphocytes correlate 
with outcome after ASCT in NHL and MM patients (Porrata et al. 2004a, Porrata et al. 2004b, 
Katipamula et al. 2006). However, not all studies have been able to confirm this association 
(Percy et al. 2012). Lymphocyte engraftment has been faster after ASCT when more 
lymphocytes have been infused following HDT (Porrata et al. 2004b, Hiwase et al. 2008b). 
Furthermore, a faster lymphocyte recovery has been linked with superior outcome post-
transplant (Yoong et al. 2005, Hiwase et al. 2008b). Relative proportions of infused lymphocyte 
subsets may also have an impact on the lymphocyte engraftment. Furthermore, lymphocyte 
subsets at the engraftment may predict early infectious complications after ASCT (Lee et al. 
2012). 
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The lymphocyte count in stem cell grafts may be linked with mobilization therapy used. In 
the patients with NHL, the combination of plerixafor and G-CSF results in a higher amount of 
lymphocytes in the stem cell grafts than mobilization with G-CSF only (Holtan et al. 2007). On 
the other hand, mobilization with G-CSF alone has resulted in a higher amount of lymphocytes 
in the stem cell grafts than mobilization with chemotherapy plus G-CSF (Hiwase et al. 2008a). 
2.5.3.1. T lymphocytes 
T cells (CD3+) are essential for the cell-mediated immunity. T cells can be divided into two main 
subclasses, CD4-positive helper T cells (CD3+CD4+), and CD8-positive cytotoxic T cells 
(CD3+CD8+). CD4- and CD8-positive T are divided further into smaller subclasses as naïve T 
cells, memory T cells, and regulatory T cells. Many different T cell populations are present in 
stem cell grafts (Condomines et al. 2006). 
Higher numbers of CD4+ cells in the graft and an increased CD4/CD8 ratio have been shown 
to be associated with prolonged EFS after ASCT in MM patients (Schmidmaier et al. 2008). The 
corresponding phenomenon has been observed also with CD8+ cells (Atta et al. 2009). In 
addition, a lower ratio of CD4+ to CD8+ cells in the infused graft has been reported to be an 
independent risk-factor for severe mucositis in MM patients after HDT (Lee et al. 2012). On the 
other hand, a higher number of infused CD26+ T cells was associated with poorer outcome after 
ASCT (Hildebrandt et al. 2012). Infusing a higher number of CD4+ T cells may reduce the 
incidence of moderate and severe infections after ASCT (Menéndez et al. 2002).  
2.5.3.2. Natural killer (NK) cells 
NK cells (CD3-CD16/56+) are cytotoxic lymphocytes that are a part of adaptive innate immunity. 
NK cells have been shown to be the first lymphocyte population that recovers after 
hematopoietic stem cell transplantation (Porrata and Markovic 2004). The amount of re-infused 
NK cells has been correlated with absolute lymphocyte count recovery after transplantation in 
patients with MM or NHL (Porrata et al. 2003). In addition, NHL patients with a higher amount 
of NK cells in the peripheral blood at day +15 after ASCT have had a better OS and PFS after 
transplantation in one study (Porrata et al. 2008). 
2.5.3.3. B lymphocytes 
Johnsen et al. (Johnsen et al. 1998) have reported that potentially malignant CD19+ B-
lymphocytes are mobilized during stem cell mobilization in patients with MM or NHL. In their 
study, more than 10% of the analyzed leukapheresis products contained at least than 5% CD19+ 
cells. Re-infused CD19+ may participate in immunological reconstitution after ASCT 
(Bomberger et al. 1998, Lee et al. 2012). Mobilization of CD19+ cells has also been confirmed in 
healty inviduals (Hassan et al. 1996). 
2.5.4. Dendritic cells (DC) 
The main function of dendritic cells (DC) is to process antigens and present them to other 
immunologically active cells. Higher pre- and post-transplant levels of DCs have been 
correlated with better survival after ASCT in patients with DLBCL (Dean et al. 2005). 
Administration of GM-CSF combined with G-CSF may improve DC reconstitution after 
autologous stem cell transplantation when compared to patients treated with G-CSF alone 
(Eksioglu et al. 2011).  
It has been reported that plerixafor may induce mobilization of precursor dendritic cells 
(pDC1) (type 1) and pDC2 (type 2) populations, but does not have an effect on the pDC1/pDC2 
ratio (Gazitt et al. 2007). 
2.5.5. Granulocytes 
Although the apheresis system is aimed to collect cells from the mononuclear fraction, also 
polymorphonuclear (PMN) cells are collected, and can be found in the leukapheresis product 
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(Menéndez et al. 2002, Pierelli et al. 2012). It is likely that most of these PMN cells with a short 
half-life lose their biological functions and vanish during cryopreservation (Price and Dale 1978, 
Reich-Slotky et al. 2008). However, some PMN cells may recover and be active after storage in 
the vapor or liquid phase of liquid nitrogen (Richman et al. 1983, Foïs et al. 2007). High levels of 
granulocytes in the stem grafts have been suspected to cause adverse events during re-infusion 
(Cordoba et al. 2007, Khera et al. 2012). 
2.5.6. Tumor cells 
The role of tumor cells in stem cell grafts is controversial (DiPersio et al. 2011). Many studies 
have reported that the amount of tumor cells in the stem cell grafts do not have an influence on 
PFS or OS in patients with MM or NHL (Demirkazik et al. 2001, Blystad et al. 2004, Ho et al. 
2009). However, controversial results have also been reported (López-Pérez et al. 2000, Vogel et 
al. 2005, Kopp et al. 2009). While it is possible that tumor cells in the stem cell graft could cause 
a relapse, it is more likely that relapse is due to an insufficient eradication of tumor cells in the 
patient (DiPersio et al. 2011). This concept is corroborated by the results from the studies 
investigating the impact of CD34+ cell selection from the stem cell grafts (Dreger et al. 1999, 
Stewart et al. 2001, Remes et al. 2003, Bourhis et al. 2007). There are no data from randomized 
studies suggesting that some form of positive or negative selection in order to reduce tumor cell 
contamination of grafts results in superior patient outcomes after HDT.  
 
Table 3. Graft characteristics of potential importance in autologous setting (modified from Jantunen 
and Fruehauf 2011). 
 
Parameter Reported impact  
CD34+ cell dose Engraftment, outcome  
CD34+ subclasses Engraftment  
Lymphocyte subsets Immunological recovery, outcome  
NK cells Immunological recovery, outcome  
DCs Immunological recovery, outcome  
Tumor cells Outcome  
Other cell types Adverse effects at re-infusion  
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3 Aims of the Study 
The aim of this retrospective study was to investigate the effects of the new stem cell mobilizing 
agent plerixafor in ASCT. The more specific study aims were: 
 
To evaluate the kinetics of the white blood cell count and CD34+ cells after 
chemomobilization in poor and standard mobilizers to create an algorithm for pre-
emptive use of plerixafor (I) 
 
 
To explore the effects of plerixafor injection on CD34+ cell mobilization and WBC 
differential counts (II) 
 
 
To assess the effects of plerixafor injection on graft lymphocyte subsets and 
lymphocyte viability (III - V) 
 
 
To assess the effects of plerixafor injection on CD34+ cell subclasses and viability of 
CD34+ cells in the collected blood graft (IV, V) 
 
 
To investigate the effects of plerixafor on short and long-term engraftment and 
outcome after ASCT (III - VI) 
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4 Patients and Methods 
4.1. PATIENTS 
4.1.1. Kinetics of CD34+ cell mobilization and implications for pre-emptive plerixafor use 
(study I) 
A total of 390 first-time chemomobilized patients with hematological malignancies from Kuopio 
University Hospital mobilized between 1 January 2001 and 31 December 2010 were analyzed in 
the study. The main disease entities were NHL (181 patients, 46%), MM (152 patients, 39%), and 
HL (33 patients, 8%). Patients were grouped according to their CD34+ mobilization. Group A 
included patients with very poor mobilization (maximum B-CD34+ *

!
\
"6/L; n=29) and 
group B included patients with inadequate mobilization (maximum B-CD34+ count 6–10 x 106/L; 
n=14). Group C consisted of standard mobilizers (only patients who were mobilized from 1 
August 2009 to 30 July 2010 and collected CD34+ 	
 ?
 @
 \
 "6/kg with a maximum of three 
aphereses without plerixafor were included) (n=33). 
4.1.2. Characteristics of NHL patients (studies II-IV, VI) 
4.1.2.1. Effects of plerixafor injection on blood white blood cell (WBC) composition and 
CD34+ cell mobilization (study II) 
In study II, 39 patients with NHL were mobilized with chemotherapy plus G-CSF between 
April 2009 and March 2011, and were admitted for stem cell apheresis to the hematological 
ward at Kuopio University Hospital (Table 4). Twenty of the patients also received plerixafor. 
The most common indication for plerixafor use was insufficient stem cell mobilization. All 
patients in the control grou
 
 	*		=*
 ^
 ^
 ^
 ?
 @
 \
 "6/kg CD34+ 
cells) by 1–2 apheresis without plerixafor. Twelve out of 20 (60%) plerixafor-treated patients 
were included in subsequent studies III and IV evaluating cellular composition of collected 
grafts. 
4.1.2.2. Effects of plerixafor injection on the collected blood graft CD34+ cell subclasses, 
lymphocyte subsets and lymphocyte viability (studies III - IV) 
In study III, 24 patients with NHL were mobilized with chemotherapy plus G-CSF. Thirteen of 
these patients additionally received plerixafor (Table 4). The control group consisted of 11 NHL 
patients who received mobilization with chemotherapy plus G-CSF and in whom 2 x 106 to 6 x 
106/kg CD34+ cells were collected with 1–2 apheresis procedures without plerixafor. 
In study IV, 34 patients were included (Table 4). Nineteen patients (56%) received plerixafor 
pre-emptively after mobilization with chemotherapy plus G-CSF. The control group consisted 
of 15 patients with NHL who received chemomobilization and were successfully collected 
without plerixafor with 1–2 aphereses. All patients included in Study III were included also in 
the subsequent Study IV with some additional patients. 
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Table 4. Characteristics of NHL patients in studies II - IV.  
 
 Study II, n=39 Study III, n=24 Study IV, n=34 
Stem cell mobilization with 
plerixafor, n (%) 
20 (51%) 13 (54%) 19 (56%) 
Stem cell mobilization without 
plerixafor, n (%) 
19 (49%) 11 (46%) 15 (44%) 
Gender, n (%)    
 Male %) 17 (71%) 26 (76%) 
 Female %) 7 (29%) %) 
Age (years), median (range) 	–  52 (31 – 66) 54 (29 – 66) 
Histology, n (%)    
 DLBCL 	 12 (50%) 15 (44%) 
 FL 9 (23%) 6 (25%) 9 (26%) 
 MCL 9 (23%) 5 (21%)  
 PTCL 6 (15%) 1 (4%) 4 (12%) 
Mobilization, n (%)    
 CY 6 (15%)  2 (6%) 
 DHAP 5 (13%) 6 (25%) 11 (32%) 
 HD-AraC 24 (62%)  	 
 ICE 	  3 (9%) 
 CHOP 1 (3%) - - 
G-CSF used in mobilization, n (%)    
 pegfilgrastim 25 (64%) 17 (71%) 25 (74%) 
 filgrastim 14 (36%) 7 (29%) 9 (26%) 
Abbreviations: DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; PTCL, 
peripheral T-cell lymphoma; CY, cyclophosphamide; DHAP, dexamethasone, high-dose cytarabine, cisplatin; HD-
AraC, high-dose cytarabine; ICE, ifosfamide, carboplatinum, etoposide; CHOP, cyclophosphamide, doxorubicin, 
vincristine, prednisolone. 
4.1.2.3. Engraftment and outcome after ASCT (Study VI)  
Study VI included 89 consecutive NHL patients from Kuopio and Oulu University Hospitals 
who received ASCT between January 2009 and December 2011. All patients were initially 
mobilized with chemotherapy plus G-CSF. Thirty-three of these patients received also 
plerixafor. The rest of the patients (n=56, 63%) served as a control group. The median age of the 
patients was 57 years (range 26 – 71). The plerixafor group included more relapsed patients 
(52% vs. 32%, p=0.071) and more lymphomas with aggressive histology (DLBCL, PTCL, or 
Burkitt's lymphoma (BL)) (63% vs. 44%, p=0.083). The proportion of patients in CR at the time of 
stem cell mobilization was 58% (n=19) in the plerixafor group and 48% (n=27) in the control 
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group (p=0.393). High-dose cytarabine was the most commonly used mobilization therapy in 
both groups. Detailed patient and mobilization characteristics are presented in Table 5. 
 
Table . Characteristics of NHL patients in study VI.  
 
 Stem cell mobilization with 
plerixafor, n=33 
Stem cell mobilization 
without plerixafor, n=56 
Gender, n (%)   
 Male 22 (67%) 43 (77%) 
 Female 11 (33%) 13 (23%) 
Age (years), median (range) 	–  57 (26 – 71) 
Histology, n (%)   
 DLBCL* 15 (45%) 19 (34%) 
 FL 7 (21%) %) 
 MCL 3 (9%) 17 (30%) 
 PTCL %) 12 (21%) 
 Burkitt 2 (6%) - 
Mobilization, n (%)   
 CY 3 (9%) 4 (7%) 
 DHAP  11 (20%) 
 HD-AraC 17 (52%) 26 (46%) 
 ICE/IVAC/IVE/MINE %) 5 (10%) 
 CHOP/CHOEP 1 (3%) 5 (9%) 
 Bonn C 0 5 (9%) 
G-CSF used in mobilization, n (%)   
 pegfilgrastim %) 32 (57%) 
 filgrastim 15 (46%) 24 (43%) 
Abbreviations: DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; PTCL, 
peripheral T-cell lymphoma; CY, cyclophosphamide; DHAP, dexamethasone, high-dose cytarabine, cisplatin; HD-
AraC, high-dose cytarabine; ICE, ifosfamide, carboplatinum, etoposide; IVAC, ifosfamide, etoposide, high-dose 
cytarabine; IVE, ifosfamide, epirubicin, etoposide; MINE, mesna, ifosfamide, mitoxantrone, etoposide; CHOP, 
cyclophosphamide, doxorubicin, vincristine, prednisolone; CHOEP, cyclophosphamide, doxorubicin, etoposide, 
vincristine, prednisolone; Bonn C, high-dose cytarabine, vindesine, dexamethasone.  
* including two patients with primary central nervous system lymphoma (PCNSL) in the plerixafor group and six 
patients in the control group 
4.1.3. Characteristics of MM patients (study V) 
In study V, 21 MM patients were mobilized between April 2010 and March 2011 in Kuopio and 
Tampere University Hospitals. Seventeen patients (81%) were mobilized with CY 2 g/m2 plus  
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G-CSF. The rest of the patients (n=4, 19%) were mobilized with G-CSF. In addition, all G-CSF-
mobilized patients and five chemomobilized patients (29%) received plerixafor. The control 
group included twelve patients who were mobilized with CY 2 g/m2 plus G-CSF, and at least 2.0 
x 106 CD34+ cells/kg collected with 1–2 aphereses. Patient characteristics are presented in Table 6 
and Study V, Table 1. 
 
Table 6. Characteristics of MM patients in study V.  
 
 Stem cell mobilization with  
plerixafor 
Stem cell mobilization without 
plerixafor 
Number of patients, n 9 12 
Gender, n (%)   
 Male 5 (56%) 5 (42%) 
 Female 4 (44%) %) 
Age (years), median (range) 59 (53 – 67) 62 (42 – 70) 
Chemomobilization, n (%) 5 (56%) 12 (100%) 
Filgrastim used as G-CSF in 
mobilization, n (%) 
4 (44%) 6 (50%) 
Pegfilgrastim used as G-CSF in 
mobilization, n (%) 
5 (56%) 6 (50%) 
4.2. METHODS 
4.2.1. Clinical methods 
4.2.1.1. Mobilization of stem cells 
In NHL patients, the mobilization regimens consisted of disease-specific chemotherapy, usually 
high-dose cytarabine or intermediate-dose cyclophosphamide (4 g/m2). In MM patients, either 
low-dose cyclophosphamide (2 g/m2) or G-CSF alone was used. Either filgrastim or 
pegfilgrastim were used as a growth factor. In case of poor mobilization or low collection yield, 
the patients treated with pegfilgrastim received an extra dose of filgrastim followed by 
plerixafor injection. The most common plerixafor dose was 240 μg/kg. Detailed mobilization 
methods and growth factors used are presented in Tables 4-6. 
4.2.1.2. Collection of stem cells 
Blood samples for measurements of blood WBC differential and CD34+ counts taken daily in the 
morning were started routinely when WBC count exceeded 0.5 x 109/L (1.0 x 109/L in Tampere 
University Hospital, study V). Measurements were continued until completion of aphereses or 
when the mobilization failure was observed. 
Stem cell aphereses were started routinely if the morning B-CD34+ counts exceeded 20 x 
106/L. However, in individual patients apheresis was started with rising B-CD34+ counts 
between 5-19 x 106/L, because it was anticipated that higher B-CD34+ counts were not to be 
expected due to stable or slowly increasing B-CD34+ counts. Collections were finished when the 
target yield had been reached or if collection failure was apparent. Collections were performed 
with a COBE Spectra AutoPBSCTM cell separator (Cobe BCT, Lakewood, CO). The blood volume 
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processed daily was 2.5 times by the patient’s estimated blood volume, and it took four to five 
hours.  
In NHL patients, the minimum target of the CD34+ cells was 2 x 106/kg both in Oulu 
University Hospital and Kuopio University Hospital. In Study V (MM patients), the minimum 
target was 2 x 106/kg CD34+ cells for a single transplant in Kuopio University Hospital, and 4 x 
106/kg ~_
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transplants. In Tampere University Hospital the collection target was 4 x 106/kg CD34+ cells for a 
single transplant and 8-10 x 106/kg in patients with option for tandem transplants, respectively. 
4.2.1.3. High-dose therapy 
In studies III and IV, all patients with NHL received as conditioning a BEAM regimen 
(carmustine 300 mg/m2 on d -6, etoposide 200 mg/m2 d -5 to d -2, cytarabine 300 mg/m2 d -5 to d 
-2 and melphalan 140 mg/m2 on day -2). BEAM was also the most common (n=56, 63%) high-
dose regimen in study VI. Other regimens used for NHL patients in study VI included BEAC 
(carmustine 300 mg/m2 on d -7, etoposide 200 mg/m2 d -6 to d -3, cytarabine 400 mg/m2 d -6 to d 
-3, and cyclophosphamide 35 mg/kg d -6 to d -3) (n=19, 21%) or ibritumomab-tiuxetan with 
BEAC (Z-BEAC) (n=3, 3%). Patients with primary CNS lymphoma were treated with a 
combination of carmustine (400 mg/m2 on d -6) and thiotepa (10 mg/kg d -5 and d -4) (n=11, 
12%). In all MM patients (study V), HDT consisted of high-dose melphalan (200 mg/m2) as a 
single dose. G-CSF was used after stem cell graft infusion in all NHL patients. 
4.2.2. Laboratory methods 
4.2.2.1. White blood cell differential counts 
WBC differential was measured by automated analysers, most commonly with an ADVIA 2120R 
hematology system (Siemens Healthcare Diagnostics, Deerfield, IL). If an automated analysis 
failed, differential was counted manually by using May-Grünwald-Giemsa staining and 
microscopic examination of the blood smears. 
4.2.2.2. Enumeration of CD34+ cells in the blood and leukapheresis product 
The percentage of CD34+ cells, the CD34+ cell content of cryopreserved apheresis products and 
B-CD34+ counts were analyzed by flow cytometry. Most analyses were performed with a 
FACSCanto flow cytometer (Becton Dickinson, San Jose, CA), (Fig. 4), and Stem-Kit 
(Immunotech SAS/Beckman Coulter, Marseille, France) enumeration kit was used. In study V, 
samples of patients from Tampere University Hospital were analyzed with FACSCanto or 
FACSCalibur flow cytometers (Becton Dickinson, San Jose, CA), and a ProCount (Becton 
Dickinson, San Jose, CA) enumeration kit was used. In study VI, samples from patients in Oulu 
University Hospital were analyzed with FACSSort or FACSCalibur flow cytometers (Becton 
Dickinson, San Jose, CA), using a ProCount enumeration kit (Becton Dickinson, San Jose, CA). 
ISHAGE protocol for a single platform method was used. Gating was based on light scattering 
and immunophenotypic properties of the counted cells. The flow cytometer used and the gating 
strategy are shown in detail in Figs. 5 and 6. 
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Figure . Becton Dickinson FACSCanto™ flow cytometer. 
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Figure 6. Gating strategy for B-CD34+ enumeration. 
4.2.2.3. Laboratory processing and cryopreservation of the grafts 
Apheresis products were processed at the stem cell laboratory (the Laboratory of Eastern 
Finland, Kuopio, Finland). The grafts were not manipulated (e.g. purging or washing post-
thaw). DMSO was added to the products to protect cells during the cryopreservation, using a 
final concentration of 10%. Graft samples (0.5 ml) were taken before cryopreservation, and these 
samples were handled in a similar way as the other apheresis products. These samples were 
originally intended for quality control, but were also used for research purposes in the present 
studies. The products were frozen in the liquid nitrogen freezer using a controlled rate-freezing 
program, and maintained in the vapor phase of the liquid nitrogen refrigerator until analyses. 
The median graft sample preservation times from the collection to the flow cytometric analysis 
are presented in the original publications (Studies III-V). 
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4.2.2.4. Flow cytometry of frozen grafts (studies III-V) 
The samples of the cryopreserved leukapheresis products were thawed in the Laboratory of 
Eastern Finland (Kuopio, Finland), in a +37°C water bath immediately before the flow 
cytometric analysis.  
In Studies IV-V, the samples of cryopreserved leukapheresis products were stained for CD34+ 
subtyping with antibodies (Ab) according to standard procedures and analyzed with 
FACSCanto flow cytometry (Becton Dickinson, San Jose, CA). 7-AAD was used to exclude dead 
cells from the analysis. Ab’s against the following cell-surface markers were used (clone 
designations are given in parenthesis): CD34 (8G12), CD38 (HB7), CD133 (AC133), and CD45 
(2D1). All antibodies were obtained from Becton Dickinson (Heidelberg, Germany), except for 
CD133 (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). The gating strategy for CD34+ 
subtyping is presented in Fig. 7. 
 
 
Figure 7. Gating strategy for CD34+ cell subtyping. 
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BDMultitest CD3/CD8/CD45/CD4 and CD3/CD16+ CD56/CD45/CD19 reagents (Becton 
Dickinson, Heidelberg, Germany) with BD Trucount tubes (Becton Dickinson, Heidelberg, 
Germany) were used with FACSCanto flow cytometry to determine the absolute numbers of T, 
B, and NK cells as well as the CD4 and CD8 subpopulations in the graft. The viability of 
lymphocytes was measured using 7-AAD staining.  
Frozen samples of the first graft collected after plerixafor injection, and in the control group, 
of the first graft collected, were thawed and evaluated by flow cytometry. The exception was in 
study IV where in addition to the graft collected after plerixafor injection, also the first graft 
collected was evaluated in five patients.  
The data of the CD34 measurements were analyzed using BD FACSDiva software and the 
data of the lymphocyte subsets using BD FACSCanto software (Becton Dickinson, San Jose, 
CA). The cell content of the graft was calculated by multiplying the concentration of each cell 
population with the graft volume and dividing that by patient weight (kg).  
4.2.2.5. Colony forming unit-granulocyte/macrophage (CFU-GM) assay (studies III-V) 
The in vitro growth of CFU-GM was assessed routinely from all grafts after collection. A few 
days after freezing, the samples from cryopreserved leukapheresis products were thawed in 
+37°C water bath and suspended in IMDM with l-glutamine (Gibco, Paisley, UK). The cell 
suspension was dispensed into methylcellulose medium containing recombinant human 
cytokines (MethoCult H4434 Classic, StemCell Technologies, Vancouver, British Columbia, 
Canada). The methylcellulose medium was aliquoted into two Petri dishes, and the dishes were 
incubated in a humidified 37°C incubator with 5% CO2 for a total of 14 days and studied using 
an inverted microscope. CFU-GMs were enumerated in both dishes and the results were used 
to calculate the absolute number of CFU-GMs per patient weight (kg). The total number of 
incubated cells was not standardized. Therefore, the CFU-GM assay used should be considered 
as a qualitative test instead of being quantitative.   
4.2.3. Quality assurance 
All participating transplantation centers (Kuopio University Hospital, Oulu University 
Hospital, and Tampere University Hospital) were supervised by the Finnish Medicines Agency 
(Fimea). The Laboratory of Eastern Finland conducted external quality assessment programs for 
the CD34 and lymphocyte subset measurements (both 6 times a year) organized by the United 
Kingdom National External Quality Assessment Service (UK NEQAS) and for the 
hematopoietic progenitor assays (two times a year) organized by Stemcell Technologies Inc. 
(Vancouver, Canada). 
4.2.4. Data collection 
Clinical patient data were collected from hospital data systems using a specifically designed 
information retrieval form. All forms were blinded to enhance the protection of privacy.  
4.2.5. Statistical methods 
In Study I, Fisher’s exact test was used as a statistical significance test. In addition, sensitivity, 
specificity, positive and negative predictive values were calculated. In other studies, the Mann-
Whitney U test, Wilcoxon signed-rank test, Pearson's chi-squared test, Kaplan-Meier and Log-
Rank test were used to analyze data. A two-tailed p value of less than 0.05 was considered 
statistically significant. All calculations and statistical analyses except for Fisher’s exact test 
were conducted using SPSS Statistics (version 19.0 in studies I and II and version 20.0 in other 
studies) for Windows (SPSS Inc., Somers, NY). Fisher’s exact test was calculated with GraphPad 
Prism (GraphPad Software Inc., La Jolla, CA).  
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4.3. APPROVALS 
The study protocol was approved by the Ethical Committee of the Kuopio University Hospital 
and the National Supervisory Authority for Welfare and Health (Valvira). Permission for 
analysing the graft samples and collecting the follow-up data was also authorized by the 
Valvira. 
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5 Results 
5.1. MOBILIZATION KINETICS OF CD34+ CELLS AND IMPLICATIONS FOR 
PRE-EMPTIVE PLERIXAFOR USE (STUDY I) 
The incidence of poor mobilization was highest among patients with Waldenstrom's 
macroglobulinemia. However, the number of these patients was very low in this series. The risk 
of poor or inadequate mobilization was substantially higher in NHL patients than in patients 
with MM (17% vs. 1.3%, respectively, p < 0.001).  Detailed data on the incidences of very poor or 
inadequate mobilization are presented in Table 7. 
 
Table 7. Incidence of poor or inadequate mobilization in different diseases (Study I). 
 
Disease 
Group A, very poor mobilization 
(maximum B-CD34+106/L)  
(n=29) 
Group B, inadequate mobilization 
(maximum B-CD34+ 6–10×106/L) 
(n=14) 
NHL (n=181) 20 (11%) 11 (6%) 
MM (n=152) 1 (0.7%) 1 (0.7%) 
HL (n=33) 2 (6%) 1 (3%) 
CLL (n=15) 3 (20%) 0 (0%) 
Waldenstrom's  
macroglobulinemia  
(n=6) 
3 (50%) 1 (17%) 
In the group of poorly mobilizing patients (group A, maximum B-CD34+ *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"6/L), the 
median WBC count at the time of highest CD34+ count measured was 8.1 x 109/L (range 1.9–
21.6). The mobilization kinetics of these patients are presented in Fig 7. Due to poor stem cell 
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2 x 106/kg CD34+ cells) was not achieved. Apheresis was attempted only in one patient in group 
A. Two patients in group A were later remobilized and two proceeded to marrow collection, 
but only four patients (14% of patients in the group A) proceeded to ASCT. 
In the group of inadequate mobilizers (group B, maximum B-CD34+ count measured 6-10 x 
106/L), the median WBC count at the time of maximum CD34+ count was 11.0 x 109/L (range 3.2–
|!|
The kinetics of B-CD34+ cell counts in relation to WBC counts are presented in Fig. 7. No 
patient in group B received plerixafor. Apheresis was started in 13 patients (93%).  The median 
number of collections was 2 (range 1–4) with a ^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CD34+ cells (range 0.4–1.9). Nine patients (64%) proceeded to ASCT in this group. 
The median number of aphereses was one 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106/kg CD34+ cells with maximum of three aphereses, plerixafor-treated patients excluded). In 
this group, the median stem cell yield was 2.9 x 106/kg CD34+ cells (range 2.4–12.3). The 
mobilization kinetics in this group is presented in Fig 7. 
Based on the collected data and statistical tests, four algorithms based on B-CD34 counts 
were constructed. A<


!
\
"9/L and B-CD34+ 
"
\
"6/L) was found to be the 
most suitable for separating patients who might benefit from plerixafor injections from those 
who mobilize sufficiently well without plerixafor. The algorithms are presented in Tables 8 and 
9.  
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Figure 7. Kinetics of WBC and B-CD34+ cell mobilization in group A (B-CD34+ 106/L), 
group B (B-CD34+ maximum 6-10 x 106/L), and group C (standard mobilizers, collection of >2 x 
106/kg CD34+ 	!") in study I. Only patients with at least two measurements for 
WBC and B-CD34+ counts are shown. 
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Table 8. Summary of algorithms for pre-emptive plerixafor use. 
 
 
Yes No Number of patients with 
WBC counts and CD34+ 
counts not available 
Algorithm I (WBC >5 x 109/L and B-CD34+ 6/L) 
Group A (n=29) 19 (66%) 0 (0%) 10 (34%) 
Group B (n=14) 3 (21%) 11 (79%) 0 (0%) 
Group C (n=33) 0 (0%) 28 (85%) 5 (15%) 
Algorithm II (WBC >5 x 109/L and B-CD34+ 6/L) 
Group A (n=29) 19 (66%) 0 (0%) 10 (34%) 
Group B (n=14) 14 (100%) 0 (0%) 0 (0%) 
Group C (n=33) 1 (3%) 27 (82%) 5 (15%) 
Algorithm III (WBC >10 x 109/L and B-CD34+ 6/L) 
Group A (n=29) 9 (31%) 0 (0%) 20 (69%) 
Group B (n=14) 0 (0%) 12 (86%) 2 (14%) 
Group C (n=33) 0 (0%) 19 (58%) 14 (42%) 
Algorithm IV (WBC >10 x 109/L and B-CD34+ 6/L) 
Group A (n=29) 9 (31%) 0 (0%) 20 (69%) 
Group B (n=14) 12 (86%) 0 (0%) 2 (14%) 
Group C (n=33) 0 (0%) 19 (58%) 14 (42%) 
Table 9. Summary statistics of algorithms for pre-emptive plerixafor use. 
 
 Algorithm I Algorithm II  Algorithm III Algorithm IV 
Significance (Fisher’s exact test) p<0.001 p<0.001 p=0.001 p<0.001 
Sensitivity 1.00 0.97 1.00 1.00 
Specificity 0.72 1.00 0.61 1.00 
Positive predictive value 0.67 1.00 0.43 1.00 
Negative predictive value 1.00 0.96 1.00 1.00 
5.2. EFFECTS OF PLERIXAFOR INJECTION ON BLOOD CD34+ CELL 
MOBILIZATION AND WBC COMPOSITION (STUDIES II, VI) 
The first injection of plerixafor significantly increased WBC, neutrophil, lymphocyte, 
eosinophil, monocyte and mononuclear cell (MNC) counts when compared to the morning 
values preceding plerixafor injection. In study II, the median B-CD34+ count increased from 3 x 
106/L (range <1 – 25) to 27 x 106/L (range <1 – 81) with a median 5-fold increase (range 1 – 17, p < 
0.001). The B-CD34+ count in the morning of the first plerixafor dose (pre) and about 8 hours 
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after (post) in 20 NHL patients are shown in Fig 8. There were no significant differences in these 
parameters in plerixafor-treated patients who received either filgrastim or pegfilgrastim as a G-
CSF. However, in study VI, the median fold-increase in the B-CD34+ count after the first 
plerixafor injection was 4.1 (range 1.2 – 19.0) among the filgrastim-treated patients and 7.2 
(range 2.0 – 17.0) among the pegfilgrastim-treated patients (p=0.027). 
In the control group, the median B-CD34+ count increased from 6 x 106/L (range 1 – 17) to 34 x 
106/L (range 16 – 123) with a median 7-fold increase (range 1 – 25) from the day prior to the first 
apheresis to the morning value of the day of the first apheresis (p < 0.001).  
 
 
Figure 8. B-CD34+ counts in the morning of the first plerixafor dose and 8 h after (study II). 
 
WBC, neutrophil, lymphocyte, eosinophil, monocyte and MNC counts increased between the 
observed time points also in the control group patients. WBC counts were significantly higher 
in the plerixafor group than in the control group on the first collection morning, (21.5 vs. 9.1 x 
109)/L, p < 0.001). In addition, the count of neutrophils (16.8 vs. 4.0 x 109/L, p < 0.001), 
lymphocytes (2.0 vs. 1.1 x 109/L, p=0.053), monocytes (1.3 vs. 0.6 x 109/L, p=0.001), eosinophils 
(0.4 vs. 0.1 x 109/L, p=0.061), and MNCs (3.2 vs. 1.8 x 109/L, p=0.01) was higher in the plerixafor 
group. The median B-CD34+ count was higher in the control group (34 vs. 27 x 106/L, p=0.043). 
Detailed data are presented in Tables 10 and 11. 
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Table 10. CD34+ and WBC counts and WBC differential in NHL patients before and after the first 
plerixafor dose. The data are presented as median (range). 
 
 Morning prior to the first 
plerixafor dose 
After the first plerixafor dose 
(next morning) 
Significance 
p 
WBC (x 109/L)  6.6 (2.1 – 35.2) 21.5 (5.2 – 73.2) <0.001 
B-CD34+ (x 106/L) 3 (< 1 – 25) 27 (< 1 – 81) <0.001 
Neutrophils (x 109/L) 5.3 (1.2 – 32.1) 16.8 (4.3 – 53.4) <0.001 
Lymphocytes (x 109/L) 0.7 (0.1 – 2.8) 2.0 (0.5 – 5.9) <0.001 
Monocytes (x 109/L) 0.5 (0.1 – 2.1) 1.3 (0.3 – 7.3) <0.001 
Eosinophils (x 109/L) 0.1 (0.0 – 0.5) 0.4 (0.0 – 2.7) 0.001 
MNC abs. (x 109/L) 1.5 (0.5 – 4.9) 3.2 (0.7 – 10.6) <0.001 
Table 11. Comparison of CD34+ and WBC counts in NHL patients mobilized without plerixafor on the 
morning preceding the first apheresis and on the morning of the first apheresis. The data are 
presented as medians (range). 
 
 Day prior to the  
first apheresis 
In the morning of the day of 
the first apheresis 
Significance 
p 
WBC (x 109/L)  2.1 (0.7 – 6.4) 9.1 (1.5 – 15.8) <0.001 
B-CD34+ (x 106/L) 6 (1 – 17)* 34 (16 – 123) <0.001 
Neutrophils (x 109/L) 0.5 (0.0 – 2.7) 4.0 (0.5 – 13.2) <0.001 
Lymphocytes (x 109/L) 0.7 (0.2 – 4.7) 1.1 (0.3 – 5.3) 0.002 
Monocytes (x 109/L) 0.3 (0.0 – 1.0) 0.6 (0.1 – 1.6) 0.001 
Eosinophils (x 109/L) 0.1 (0.0 – 0.6) 0.1 (0.0 – 0.6) 0.009 
MNC abs. (x 109/L) 0.9 (0.4 – 5.7) 1.8 (0.7 – 6.5) <0.001 
* data missing in two patients  
The median yield after the first collection was 2.1 x 106/kg CD34+ cells (range 0.6 – 6.1) in the 
plerixafor group and 2.4 x 106/kg CD34+ cells (range 1.1 – 18.6) in the control group  
(p=0.123). In nine plerixafor-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CD34+ cells) was reached after the first plerixafor dose. For comparison, 74% of the control 
group patients reached the minimal collection target with a single apheresis. There were no 
significant differences in the median total stem cell yields between the groups (2.8 x 106/kg 
CD34+ cells vs. 3.4 x 106/kg CD34+ cells, p=0.122). 
5.3. EFFECTS OF PLERIXAFOR INJECTION ON THE COLLECTED BLOOD 
GRAFT LYMPHOCYTE SUBSETS AND LYMPHOCYTE VIABILITY (STUDIES III 
- V) 
The total amount of T lymphocytes (CD3+) was significantly higher in the grafts collected from 
NHL patients after pre-emptive plerixafor injection than in grafts from the control group 
patients (p=0.004 and p=0.002). In addition, the amount of helper T lymphocytes (CD3+CD4+), 
cytotoxic T lymphocytes (CD3+CD8+) and natural killer (NK) cells (CD3-CD16/56+) were all 
significantly higher after plerixafor injection (p=0.002 and p=0.001, p=0.006 and p=0.007, p=0.045 
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and p=0.019, respectively). In MM patients there were no significant differences in any of these 
cell populations when grafts collected from plerixafor-mobilized and control patients were 
compared (p=0.279 for the CY 2 g/m2 + G-CSF + plerixafor group vs. the control group; p=0.133 
for the G-CSF + plerixafor group vs. the control group, and p=0.730 for the CY 2 g/m2 + G-CSF + 
plerixafor group vs. the G-CSF + plerixafor group). Detailed data are presented in Table 12 for 
NHL studies and Table 13 for the MM study. 
The number of B lymphocytes (CD19+) was below the detection limit by flow cytometry in 
the vast of majority of grafts collected from NHL patients. Only small amounts of B 
lymphocytes were observed in some patients (0.03-0.1% of all lymphocytes in five plerixafor 
mobilized grafts and 0.03-0.08% of all lymphocytes in four grafts in the control group (p=0.971)). 
In MM patients, there was no significant difference in the amount of B lymphocytes in grafts 
from patients mobilized either with CY 2 g/m2 + G-CSF + plerixafor or CY 2 g/m2 + G-CSF 
(p=0.160). On the other hand, the number of B lymphocytes was significantly higher in grafts 
mobilized with G-CSF + plerixafor than in grafts mobilized with CY 2 g/m2 + G-CSF + plerixafor 
or CY 2 g/m2 + G-CSF (p=0.016 and p=0.013, respectively) (Table 13).   
 
Table 12. Summary of the lymphocyte subset analysis of freezed blood grafts in NHL patients (III - 
IV). The data are presented as medians (range). 
 
 Study III Study IV 
 
Chemotherapy +  
G-CSF + plerixafor,  
n=13 
Chemotherapy + 
G-CSF,  
n=13 
Chemotherapy +  
G-CSF + plerixafor, 
 n=19 
Chemotherapy  
+ G-CSF, 
 n=15 
CD3+ cell content  
(x 106/kg) 
75.3 (14.6 – 327.3)* 21.3 (9.1 – 159.4)* 100.4 (14.6 – 327.3)* 25.0 (9.1 – 159.4)* 
CD3+CD4+ cell 
content  
(x 106/kg) 
32.7 (10.6 – 	
* 12.4 (6.9 – 51.5)* 50.9 (10.6 – 	
* 15.1 (7.0 – 54.9)* 
CD3++ cell 
content  
(x 106/kg) 
33.4 (4.2 – 200.5)* 

– 125.0)* 44.2 (4.2 – 233.0)* 10.7 (2.2 – 125.0)* 
CD19+ cell content  
(x 106/kg) 
0 (0 – 0) 0 (0 – 0) 0 (0 – 0) 0 (0 – 0) 
NK (CD3-CD16/56+)  
cell content  
(x 106/kg) 
5.1 (0.2 – 30.40)# 1.5 (0.3 – 
# 

– 30.4)# 

	– 13.7)# 
CD4+$+ cell ratio 
&
	 – 3.04) 

 – 5.06) 1.0 (0.3 – 3.0) 1.4 (0.3 – 5.1) 
Significances (comparison made between the groups within the same study): * p=<0.01, # p=<0.05. 
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Table 13. Summary of the lymphocyte subset analysis of freezed blood grafts in MM patients (V). 
The data are presented as medians (range). 
 
 
CY 2 g/m2 + G-CSF + 
plerixafor,  
n=5 
G-CSF + plerixafor,  
n=4 
CY 2 g/m2 + G-CSF,  
n=12 
CD3+ cell content  
(x 106/kg) 
61.7 (16.9 – 197.2) 

– 333.9) 40.1 (6.4 – 90.7) 
CD3+CD4+ cell content  
(x 106/kg) 
51.9 (10.2 – 126.5) 

&– 206.5) 26.6 (3.6 – 
& 
CD3++ cell content  
(x 106/kg) 
10.2 (6.9 – 
 73.0 (2.7 – 125.1) 

– 23.10) 
CD19+ cell content  
(x 106/kg) 


– 2.7)+ 

– 56.0)* 0.5 (0.1 – 53.70)*,+ 
NK (CD3-CD16/56+)  
cell content (x 106/kg) 
2.5 (1.1 – 17.6) 23.2 (2.7 – 27.6)* 3.3 (1.0 – 
* 
CD4+$+ cell ratio 2.6 (1.5 – 5.1) 1.3 (0.6 – 3.2) 2.0 (0.9 – 7.5) 
Significances: * p=<0.05 (the G-CSF + plerixafor group compared to the CY 2 g/m2 + G-CSF group), + 
p=<0.05 (the CY 2 g/m2 + G-CSF + plerixafor group compared to the CY 2 g/m2 + G-CSF group). 
 
The median proportion of nonviable lymphocytes was 10% (range 2 – 31%) in grafts collected 
from NHL patients after plerixafor injection and 14% (range 1 – 49%) in grafts collected from 
the control group patients (p=0.732). In MM patients, the median proportions were 19% (range 7 
– 43%) after CY 2 g/m2 + G-CSF + plerixafor mobilization, 8% (range 2 – 20%) after G-CSF + 
plerixafor mobilization, and 17% (range 4 – 28%) after CY 2 g/m2 + G-CSF, respectively. There 
were no significant differences in these proportions between MM patient groups (p=0.506 for 
the CY 2 g/m2 + G-CSF + plerixafor group vs. the control group, p=0.262 for the G-CSF + 
plerixafor group vs. the control group, and p=0.190 for the CY 2 g/m2 + G-CSF + plerixafor 
group vs. the G-CSF + plerixafor group). 
5.4. EFFECTS OF PLERIXAFOR INJECTION ON THE COLLECTED BLOOD 
GRAFT CD34+ CELL SUBCLASSES AND VIABILITY (STUDIES IV, V) 
In NHL patients (IV), there were no significant differences in the median amounts of CD34+ 
cells when the control group and the plerixafor group were compared. The loss of viable CD34+ 
cells during cryopreservation was also equal between the groups (p=0.430). The detailed data 
are presented in Table 14. 
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Table 14. Summary of CD34+ amounts with different mobilization methods in NHL patients (study 
IV). The data are presented as medians (range). 
 
 Chemotherapy + G-CSF +plerixafor, 
n=19 
Chemotherapy + G-CSF,  
n=15 
Original CD34+ cell content  
(x 106/kg) 
2.7 (0.6 – 6.1) 2.0 (0.6 – 5.9) 
CD34+ cell content after 
cryopreservation without 7-AAD  
(x 106/kg) 
2.0 (0.5 – 6.0) 

6 – 5.1) 
CD34+ cell content after 
cryopreservation with 7-AAD  
(x 106/kg) 
1.7 (0.4 – 4.4) 1.7 (0.2 – 4.7) 
Loss of viable CD34+ cells during 
cryopreservation (%) 
22 (0 – 63) 17 (0 – ) 
In MM patients (V), the median amounts of CD34+ cells before, after cryopreservation 
without 7-AAD, and after cryopreservation with 7-AAD were significantly higher in the control 
group than in the group of patients mobilized with CY 2 g/m2 + G-CSF + plerixafor . There were 
no significant differences when the control group and the G-CSF + plerixafor group were 
compared. There were no significant differences between groups in the loss of viable CD34+ 
cells during cryopreservation either. The detailed data are presented in Table 15. 
 
Table . Summary of CD34+ amounts with different mobilization methods in MM patients (study V). 
The data are presented as medians (range). 
 
 CY 2 g/m2 + G-CSF + 
plerixafor, n=5 
G-CSF + plerixafor,  
n=4 
CY 2 g/m2 + G-CSF,  
n=12 
Original CD34+ cell content  
(x 106/kg) 
2.1 (0.3 – 2.7) 2.4 (1.2 – 5.0) 4.0 (1.2 – 
 
CD34+ cell content after 
cryopreservation without 7-
AAD (x 106/kg) 


– 2.1) 

&– 4.7) 3.5 (1.0 – 7.4) 
CD34+ cell content after 
cryopreservation with 7-AAD  
(x 106/kg) 
1.6 (0.2 – 2.2) 1.4 (0.5 – 	
 
&
– 6.1) 
Loss of viable CD34+ cells 
during cryopreservation (%) 
24 (10 – 33) 43 (24 – 61) 30 (4 – 65) 
In NHL patients, the median proportion of primitive stem cells (CD34+CD133+CD38-) from 
CD34+CD133+ cells and from all CD34+ cells were significantly higher in the group of plerixafor-
treated patients (p=0.008 and p=0.009, respectively). The absolute amount of primitive stem cells 
was also significantly higher in the plerixafor group (p=0.003). A corresponding finding was 
also observed in MM patients as the median proportions of primitive stem cells from 
CD34+CD133+ cells and from all CD34+ cells were significantly higher in the group of plerixafor-
treated patients (p=0.048 and p=0.020, p=0.048 and p=0.020, respectively). However, in MM 
patients, there were no significant differences between these groups in the absolute amount of 
primitive stem cells (p=0.574 for the CY 2 g/m2 + G-CSF + plerixafor group vs. the control group, 
p=0.212 for the G-CSF + plerixafor group vs. the control group, and p=0.413 for the CY 2 g/m2 + 
G-CSF + plerixafor group vs. the G-CSF + plerixafor group). The detailed data are presented in 
Table 16 and Table 17. 
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Table 16. Summary of CD34+ cell subclass analysis of cryopreserved blood grafts in NHL patients 
(study IV). The data are presented as medians (range). 
 
 
Chemotherapy + G-CSF  
+ plerixafor, 
 n=19 
Chemotherapy +  
G-CSF, 
 n=15 
Proportion of CD34+CD133+	- cells from 
CD34+CD133+ cells (%) 
4.5 (1.4 – 13.4) 1.9 (0.0 – 7.7) 
Proportion of CD34+CD133+	- cells from all 
CD34+ cells  
(%) 
2.9 (1.0 – 11.6) 1.6 (0.0 – 5.9) 
The most primitive stem cell (CD34+ 
CD133+	-) content in the graft  
(x 106/kg) 
0.06 (0.01 – 0.34) 0.02 (0.00 – 0.12) 
Table 17. Summary of CD34+ cell subclass analysis of cryopreserved blood grafts in MM patients 
(study V). The data are presented as medians (range). 
 
 
CY 2 g/m2  
+ G-CSF + plerixafor,  
n=5 
G-CSF + plerixafor,  
n=4 
CY 2 g/m2 + G-CSF,  
n=12 
Proportion of CD34+CD133+	- 
cells from CD34+CD133+ cells (%) 
3.6 (0.3 – 7.1) 4.7 (1.7 – 
 

– 6.2) 
Proportion of CD34+CD133+	- 
cells from all CD34+ cells (%) 


– 6.1) 3.5 (1.4 – 7.1) 0.6 (0.1 – 4.9) 
The most primitive stem cell (CD34+ 
CD133+	-) content in the graft  
(x 106/kg) 
0.02 (0.00 – 0.10) 0.05 (0.01 – 0.14) 0.02 (0.00 – 
 
5.5. EFFECTS OF PLERIXAFOR MOBILIZED GRAFTS ON ENGRAFTMENT 
AFTER HIGH-DOSE THERAPY (STUDIES III - VI) 
The median total collected CD34+ cell doses were compared in studies II-VI. There were no 
significant differences in the median amounts between the control group and the groups of 
plerixafor-treated patients. The detailed data are presented in Table 18. 
 
Table 18. Summary of total collected CD34+ cell dose (measured before freezing) in NHL patients 
who proceeded to ASCT. The data are presented as medians (range). 
 
 Stem cell mobilization 
with plerixafor 
Stem cell mobilization 
without plerixafor 
Significance 
p 
Study II (x 106/kg) 3.2 (2.1 – 6.5) 3.4 (2.0 – 
 
& 
Study III (x 106/kg) 3.1 (1.7 – 6.5) 3.4 (1.9 – 5.9) 0.563 
Study IV (x 106/kg) 3.2 (1.7 – 6.5) 3.2 (1.9 – 5.9) 0.439 
Study VI (x 106/kg) 3.5 (2.1 – 
& 4.2 (1.9 – 
 0.076 
Early engraftment after ASCT in NHL patients was assessed in studies III, IV and VI. In 
study III, the median time from the stem cell infusion to neutrophil engraftment (neutrophils > 
0.5 x 109/L) was 10 days in both groups (range 9-17 days in the plerixafor group and 9-11 days in 
the control group) without any significant difference between the groups (p=0.092). In study IV, 
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the median time from graft infusion to neutrophil engraftment was also 10 days in both groups 
(ranges 9-17 days in the plerixafor group and 9-11 days in the control group) (p=0.773). Similar 
results were seen in study VI, in which the median engraftment time was also 10 days (ranges 8-
81 days in the plerixafor group and 8-21 days in the control group) (p=0.899). In the study of 
MM patients (V), the median time for neutrophil engraftment was 12 days (range 9-13) in the 
plerixafor group and 10 days (range 9-13) days in the control group (p=0.291). Early neutrophil 
engraftment data from Study VI are presented in Fig 9. 
 
Figure 9. Proportion of NHL patients with neutrophil engraftment (Study VI). 
 
Platelet engraftment (unsupported platelets > 20 x 109/L) was seen on day +16 (median) in the 
plerixafor group (range, 11-169 days) and on day +13 (range, 11-20 days) in the control group 
(p=0.211) in study III. In study IV, the time to platelet engraftment was 13 days in both groups 
(range 10–169 days in the plerixafor group and 11–18 days in the control group) (p=0.586), and 
in the study VI the median time was 14 days in both groups (range 10-165 days in the plerixafor 
group and 10-91 days in the control group) (p=0.083). Early platelet engraftment data from 
Study VI are presented in Fig 10. In MM patients (V), the time needed for platelet engraftment 
was 11 days in both groups (ranges 9-13 days and 10-15 days, respectively) (p=0.731). 
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Figure 	. Proportion of NHL patients with platelet engraftment (Study VI). 
 
Long-term engraftment in NHL patients was also investigated in studies III, IV and VI. In 
study III, lymphocyte and platelet counts were analyzed one, three and six months after ASCT. 
There were no significant differences between the groups in blood counts at specific time-
points. In study IV, in addition to lymphocyte and platelet counts, also hemoglobin, leukocyte 
and neutrophil counts were analyzed, with prolonged follow-up up to twelve months after 
ASCT. The leukocyte count was statistically significantly higher in the plerixafor group at six 
months after ASCT (5.4 x 109/L vs. 4.5 x 109/L, p=0.047). There were no significant differences in 
other cell populations studied. Study VI had the same follow-up parameters (cell populations) 
as study IV. In study VI, the concentration of hemoglobin was significantly higher in the control 
group at three months after ASCT (121 g/L vs. 112 g/L, p=0.009). There were no significant 
differences in other cell populations in study VI. The proportion seemed higher in the control 
group three, six and twelve months after ASCT, but differences were not statistically significant. 
Data of blood counts at specific time points are presented in the original manuscripts (Studies 
III - IV). 
5.6. OUTCOME AFTER ASCT IN NHL PATIENTS (STUDY VI)  
Outcome after ASCT in NHL patients was evaluated in study VI. The median follow-up time 
was 677 days (range 5-1340 days) in the plerixafor group and 735 days (range 12-1338 days) in 
the control group (p=0.087). 
The incidence of neutropenic fever (> 38 C, B-neutrophils < 0.5 x 109/L) was similar between 
the groups (76% in the plerixafor group vs. 71% in the control group, p=0.657). Bacteremia 
(most commonly staphylococci or enterococci) was observed in 28% of patients having 
47 
 
 
neutropenic fever in the plerixafor group and 23% in the control group, respectively (p=0.617). 
In the plerixafor group, six patients (16%) and in the control group seven patients (13%) had 
other infections (most commonly herpes zoster; 4 patient vs.  3 patients, respectively) during the 
follow-up after ASCT (p=0.464). 
Ten patients (PTCL 4, DLBCL 3, FL 2, MCL 1) in the plerixafor group and thirteen patients 
(DLBCL 6, PTCL 3, MCL 3, and FL 1) in the control group experienced a relapse after ASCT. 
PFS at one year was 79% for the plerixafor group and 86 % for the control group (p=0.399). Two-
year PFS was 70% and 83% (p=0.203), respectively. The median time from ASCT to a disease 
progression or relapse was 235 days (range 63-907 days) in the plerixafor group and 253 days 
(range 53-1102 days) in the control group (p=0.446). There was no significant difference between 
the groups in the incidence of relapse (30% vs. 23%, p=0.228).  
Nineteen patients (ten patients from the plerixafor group and nine patients from the control 
group, p=0.114) died by the end of follow-up. OS at one year was 82% for the plerixafor group and 
89% for the control group (p=0.319). Two-year OS was 71% and 85% (p=0.132) and three-year 
OS was 65% and 81% (p=0.114), respectively. The most common cause of death was progressive 
disease in both groups (seven patients from each group). In the plerixafor group, two patients 
died from septic shock a few days after stem cell infusion. These deaths were considered as 
early treatment-related mortality (TRM). One patient from the control group died from 
Influenza A virus (subtype H1N1) infection and acute respiratory distress syndrome. Two 
patients died from late non-relapse reasons (intracerebral hemorrhage and fatal abdominal 
bleeding after liver biopsy). Kaplan-Meier survival curves for PFS and OS are presented in are 
presented in Figs 11 and 12, respectively. 
 
Figure 11. Cumulative progression-free survival of NHL patients (study VI). 
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Figure 12. Cumulative overall survival of NHL patients (study VI). 
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6 Discussion 
The aim of this thesis was to investigate the effects of plerixafor in the ASCT setting. A 
significant proportion of patients mobilize inadequately, and the studies were started by 
analyzing the incidence of poor mobilization in different disease entities. In this study, an 
algorithm based on the mobilization kinetics of blood CD34+ cells in relation to WBC counts in 
chemomobilized patients was presented in an attempt to guide the use of plerixafor. Studies 
were thereafter continued by analyzing the effects of plerixafor injection on blood CD34+ cell 
counts and WBC differential counts. Stem cell subclasses and lymphocyte subsets from 
cryopreserved stem cell graft were analyzed in NHL and MM patients mobilized with and 
without plerixafor. In the last study, both short and long-term engraftment and outcome in 
plerixafor-mobilized NHL patients were evaluated.  
6.1. PATIENTS AND METHODS 
6.1.1. Patients 
All studies were retrospective and included only patients eligible for ASCT. The two main 
groups consisted of NHL patients and MM patients. These diseases are currently the main 
indications for ASCT (Passweg et al. 2013). Patients were gathered from a historical cohort of 
mobilizations and aphereses. Some patients had to be excluded from studies due to missing 
essential laboratory data or graft sample for flow cytometric analysis. 
With the exception of study I, the patient groups were relatively small. The amount of 
patients included was primarily limited by the fact that there were no more patients available at 
the time of the study in the adult hematology unit at Kuopio University Hospital. To overcome 
this issue, in two studies (V, VI), patients from two other university hospitals, Tampere and 
Oulu University Hospitals, were also included to achieve larger patient groups. The number of 
patients in these studies is quite similar to previously published studies in this field (Fruehauf 
et al. 2009, Moreb et al. 2011, Alexander et al. 2011, Taubert et al. 2011). In addition to the 
limited number of patients, the results may be affected by large inter-individual variability of 
the measures and heterogeneity of the patients. These caveats may partly explain why 
statistically significant differences were not reached for some measures despite notable 
differences in absolute median values.  
In studies II-VI, the patients were sorted into groups according to the use of plerixafor. 
Furthermore, in study V, the plerixafor group was divided into two separate groups by 
mobilization therapy (CY + G-CSF vs. G-CSF). There were no significant differences between 
the groups in regard to gender or age in any of the studies. 
In studies II-IV and VI with NHL patients, the histology of the disease was evaluated. In 
many cases, the plerixafor group had more patients with aggressive histology. This is probably 
due to several factors. Patients with more aggressive diseases (e.g. DLBCL) are likely to receive 
more intensive treatment courses than patients with indolent diseases. The number of treatment 
courses may have an impact on the ability to mobilize stem cells.  
6.1.2. Clinical methods 
In the studies included in this thesis, all but four MM patients in study V received 
chemomobilization. In NHL patients, the most commonly used mobilization regimen was 
disease-specific chemotherapy or high-dose cytarabine. The distribution of different 
chemomobilization regimens was similar between the groups. The type of disease-specific 
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chemotherapy was quite heterogeneous in study VI. This is at least in part due to the fact that 
there is no gold standard for chemomobilization regimen in NHL patients. This may cause 
some variability between the patients. It is likely that drugs or their combinations have an 
impact on the graft cellular composition, but not much is known about this. On the other hand, 
in MM patients, cyclophosphamide-based regimens are widely used for mobilization, but also 
other protocols have been applied (Wood et al. 2011). 
If stem cell mobilization was insufficient or collection yields were low, patients were treated 
with plerixafor to boost stem cell mobilization. The vast majority of patients received plerixafor 
specifically due to poor stem cell mobilization. However, the definition for poor mobilization 
varies between transplant centers, and there is no widely accepted consensus on the definition 
(Piccirillo et al. 2012). Many transplant centers use B-CD34+ cell count >20 x 106/L as a threshold 
to start collection. In some cases, plerixafor was given when adequate mobilization did not 
occur within the typical time schedule.  It is possible that in some of these patients mobilization 
would have been sufficient without plerixafor injection, but with a longer observation time. 
Some of these patients may have been late mobilizers instead of being ‘true’ poor mobilizers. 
Some patients were treated with plerixafor because of low and decreasing B-CD34 cell counts 
before the start or completion of apheresis. These patients can be considered poor mobilizers. 
The same is true for patients who had failed a previous mobilization attempt.  
The high-dose regimen BEAM was used in all patients in studies III-IV and BEAC/BEAM in 
88% of patients in study VI. In addition, all NHL patients received G-CSF after stem cell 
infusion. In MM patients, standard high-dose melphalan (200 mg/m2) was used in all patients.  
6.1.3. Laboratory methods 
All procedures were standardized and quality control was involved in blood counts and CD34+ 
cell measurements. Analyses were performed with calibrated and highly validated equipment 
used in clinical practice. International guidelines (e.g. ISHAGE) were used when possible.  
Samples of freezed grafts were used for the evaluation of cellular content in studies III-V. The 
reason was that these measurements most likely represent the post-thaw situation in clinical 
practice. The length of freezing time varied substantially due to the retrospective nature of this 
study. It is known that prolonged freezing may alter the amount and viability of cells (Liseth et 
al. 2009). However, the length of freezing time was similar between plerixafor-mobilized and 
control grafts. All flow cytometric analyses of freezed grafts were performed by the same 
qualified laboratory technician. To reduce variability, two graft samples (one from the control 
group and one from the plerixafor group) were always analyzed at the same time. 
In studies III-V, only the first graft collected after plerixafor injection or the first graft 
collected from a single patient (control group) were evaluated with flow cytometry after 
thawing the sample. Therefore, direct comparisons between graft cellular content and 
engraftment are not possible. In study VI, only data from CD34+ cell dose before freezing was 
available. 
6.1.4. Study methods 
All studies included in this thesis were retrospective. This research method has some inherent 
limitations. Retrospective study designs may also result in partly incomplete follow-up data.  
Furthermore, it should be noted that as patients were sorted by the use of plerixafor, it may 
cause imbalance between the groups. Patients who were treated with plerixafor (poor or late 
mobilizers) may be intrinsically different from standard mobilizers. Many patient-related 
factors that may have an impact in stem cell mobilization have been identified, including age, 
diagnosis, prior treatments (e.g. chemotherapy load, certain drugs, and radiotherapy), pre-
mobilization platelet count, bone marrow involvement and even gender (Drake et al. 1997, 
Micallef et al. 2000, Jantunen et al. 2003b, Kuittinen et al. 2004, Mendrone et al. 2008, Sancho et 
al. 2012). Because there was no randomization, it is possible that plerixafor-treated patients 
could have some or many of these risk factors for poor mobilization. In addition, risk factors for 
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poor mobilization may be also risk factors for poor outcome, and this should be taken into 
account when outcome after ASCT is evaluated. 
6.2. KINETICS OF CD34+ CELL MOBILIZATION AND IMPLICATIONS FOR 
PRE-EMPTIVE PLERIXAFOR USE 
Based on prior studies, 5-30% of patients considered for ASCT are hard to mobilize (Jantunen 
and Kuittinen 2008, Pusic et al. 2008, Jantunen and Kvalheim 2010, Wuchter et al. 2010). In 
study I, only 1.5% of myeloma patients belonged to the group of very poor mobilizers or 
inadequate mobilizers. Among NHL patients the proportion was as high as 17%. These figures 
are quite similar to the figures reported by others (Pusic et al. 2008, Wuchter et al. 2010, Sancho 
et al. 2012). It is possible that the proportion of very poor mobilizers might have been even 
higher in this series as some NHL patients who seemed to mobilize poorly were treated with 
plerixafor pre-emptively. In retrospect, it is difficult to determine how many of these patients 
would have been categorized as poor or inadequate mobilizers without plerixafor use.  
Because plerixafor is expensive and it may be hard to identify beforehand patients who 
mobilize poorly and require plerixafor, clinical decision models are needed to optimize its use.  
Therefore, algorithms to help this identification have been developed, but none of the published 
algorithms (Table 1) have been accepted widely for clinical use (Costa et al. 2011, Chen et al. 
2012, Sinha et al. 2011, Ozsan et al. 2012, Sancho et al. 2012, Abhyankar et al. 2012, Micallef et al. 
2013, Milone et al. 2013, Abusin et al. 2013, Hay et al. 2013). In study I, based on the 
mobilization kinetics of CD34+ cells and WBC observed and decision algorithms applied, 
algorithms II and IV were found to be the most suitable. Algorithm II (WBC > 5 x 109/L and B-
CD34+ 
"
\
"6/L) appears to be even better in finding the really hard to mobilize patients than 
algorithm IV as it was more often applicable in this retrospective study. In real life, it is very 
possible that algorithm IV (WBC > 10 x 109/L and B-CD34+ 
"
\
"6/L) might work as well as 
algorithm II. 
As plerixafor results in a median 4- to 5-fold increase in B-CD34+ when given pre-emptively 
in poor mobilizers after chemomobilization (D'Addio et al. 2011, Jantunen and Lemoli 2012), it 
is possible to estimate how many patients might have benefited from plerixafor. Some patients 
in the group of very poor mobilizers (B-CD34+ *

!
\
"6/L) would have failed to mobilize 
enough stem cells even with the addition of plerixafor. On the other hand, the majority if not all 
patients in the group of inadequate mobilization (maximum B-CD34+ count 6–10 x 106/L) might 
have had successful collections with plerixafor. 
All of tested algorithms in study I include a potential weakness as they do not take platelet 
counts into account. Platelet count is an important indicator for bone marrow recovery and the 
phase of stem cell mobilization (Ninan et al. 2007). Waiting for a few days might abolish the 
need for plerixafor use especially if the platelet counts are still low. It is also possible that some 
of the included patients were late mobilizers. Within this patient group, follow-up of WBC and 
B-CD34+ counts during mobilization should continue longer than normally. Although there are 
several suggested or even tested algorithms for pre-emptive plerixafor use in G-CSF mobilized 
patients (Costa et al. 2011, Chen et al. 2012, Sinha et al. 2011, Micallef et al. 2013), only a few 
algorithms for chemomobilized patients have been published (Ozsan et al. 2012, Sancho et al. 
2012, Milone et al. 2013, Hay et al. 2013).  
Results from study I confirmed that mobilization is difficult in a significant proportion of 
patients intended for ASCT. Poor mobilization is especially a problem among NHL patients. In 
addition, the mobilization kinetics in these patients is different from standard mobilizers. Pre-
emptive plerixafor use based on constructed decision algorithms may prove to be cost-effective 
by reducing other costs associated with mobilization and collection of stem cells. These 
algorithms need a prospective validation. 
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6.3. CD34+ CELL MOBILIZATION AND PERIPHERAL BLOOD WBC 
COMPOSITION AFTER PLERIXAFOR INJECTION 
In study II, plerixafor injection increased the blood CD34+ cells counts measured the next 
morning by a median of five-fold. This is in line with previous observations in the same setting 
(D'Addio et al. 2011, Jantunen and Lemoli 2012). In most cases, the mobilization boost induced 
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CD34+ cells) could be collected. Furthermore, an adequate graft could be collected in 85% of 
patients considered poor mobilizers. This kind of pre-emptive strategy seems to be useful as re-
mobilization or prolonged aphereses can be avoided in the majority of these patients. 
In study II, the WBC composition of peripheral blood at the time of apheresis also was 
assessed before and after plerixafor injection. The number of neutrophils was higher after 
plerixafor injection than in the control group on the morning of the first apheresis. One 
conceivable reason for this is that plerixafor was used in a later phase of mobilization in poor 
mobilizers. Higher neutrophil counts on the morning of apheresis may result in higher 
neutrophil counts also in the collection bag. This may also lead to a higher volume of DMSO to 
be infused to the patient (Tanhehco et al. 2010). Taken together, these factors may cause adverse 
effects during re-infusion of stem cell grafts (discussed earlier in Chapter 2.3.4.). In the present 
study, the median graft volumes after apheresis and after preservation were, however, similar 
between the groups. 
Blood lymphocyte counts after the first plerixafor dose were higher than in the first collection 
day in the control group. This may imply that more lymphocytes will be collected after 
plerixafor injection. The great majority of lymphocytes are likely to be T lymphocytes as the 
vast majority of patients had previously received rituximab. Detailed lymphocyte 
characterization was not performed in study II due its retrospective nature. 
Results from study II suggests that plerixafor use is associated with an increase of many 
leukocyte subtypes other than just CD34+ cells. Whether this is due to more complex 
mechanisms of action of plerixafor or due to ongoing mobilization caused by previous 
chemotherapy plus G-CSF is unknown. As the number of eosinophils, lymphocytes and 
monocytes increased also in the control group, part of the effect is likely to be associated with 
chemomobilization effect as such. It is known that many other hematopoietic cells besides 
CD34+ stem cells express CXCR4 (Aiuti et al. 1999). Thus, it is possible that these cells are also 
mobilized by plerixafor. 
6.4. LYMPHOCYTE SUBSETS OF THE FROZEN GRAFTS 
Previous studies have reported that plerixafor alone or combined with G-CSF may increase 
various lymphocyte subsets in the graft (Holtan et al. 2007, Gaugler et al. 2011). In the context of 
ASCT, lymphocytes in the graft have been primarily linked with more rapid immune recovery 
and better outcome as discussed earlier in Chapter 2.5.3. Of note, there have been no previous 
studies on the effects of plerixafor on lymphocyte subsets in chemomobilized patients where 
mobilizing chemotherapy may kill lymphocytes. 
In studies of NHL patients (III, IV), plerixafor added to chemomobilization seemed to result 
in significantly higher amounts of NK cells, total T cells, helper T cell subsets and cytotoxic T 
cell subsets in the grafts compared to the control grafts. In addition, plerixafor appears to 
increase the mobilization of T cell subsets and NK cells independently of CD34+ cell 
mobilization as the number of CD34+ cells was similar between the groups. CD19+ B 
lymphocytes were detected in very low numbers only in a few samples. An apparent reason for 
this observation is that the vast majority of patients had received rituximab as a part of their 
mobilizing chemotherapy. 
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In MM patients (study V), the number of NK cells was higher in the grafts collected after G-
CSF + plerixafor than in the grafts collected from chemomobilized patients with or without 
plerixafor. This is in line with a study by Holtan et al. (Holtan et al. 2007), where G-CSF + 
plerixafor resulted in higher number of certain lymphocyte subsets (CD3+, CD4+, CD8+) in NHL 
patients. In addition, a higher total number of lymphocytes were collected after G-CSF plus 
plerixafor than after mobilization with G-CSF alone (Holtan et al. 2007). Moreover, the amount 
of B lymphocytes was higher in the grafts collected after G-CSF plus plerixafor in MM patients 
when compared to the control group (cyclophosphamide + G-CSF) and group A 
(cyclophosphamide + G-CSF + plerixafor). The most obvious explanation for the higher number 
of B lymphocytes in MM patients mobilized with G-CSF + plerixafor (study V) is that the 
cyclophosphamide used in the other groups for mobilization purposes destroys lymphocytes. 
The broad ranges observed in the amounts of various lymphoid subsets suggest that also 
factors other than the use of plerixafor may be important in terms of mobilization of lymphoid 
cell subsets. 
As the amount of lymphoid cells in the cryopreserved grafts is about ten times higher than 
CD34+ cell counts and the majority of them are viable after thawing, they may have an impact in 
tempo and type of immune recovery after HDT. The higher number of these cells in the graft 
may be beneficial in terms of speed of immune recovery and outcome after ASCT (Porrata et al. 
2003, Porrata et al. 2004a, Porrata et al. 2004b. Hiwase et al. 2008b, Atta et al. 2009). However, 
the amount and function of NK cells in the graft has been stated to be insignificant, because 
they recover quickly post-transplant (Klingemann 2000). In this retrospective series of studies, 
evaluation of immunorecovery after ASCT was not possible. The clinical relevance of different 
lymphocyte subsets in the cryopreserved grafts remains to be elucidated. This topic will be 
specifically evaluated in the prospective GOA (Graft and Outcome in Autologous stem cell 
transplantation) study, which includes assessment of the graft cellular composition and 
immune reconstitution post-transplant (Jantunen et al. 2013b). 
This new data may have clinical relevance because a large proportion of NHL and MM 
patients are currently mobilized with a combination of chemotherapy plus G-CSF. However, 
prospective study designs with larger patient numbers and with a longer follow up are needed 
to evaluate whether the amount of various lymphocyte subsets in the grafts affects post-
transplant outcomes like severe infections or a relapse. 
6.5. CD34+ SUBCLASSES OF THE FROZEN GRAFTS 
It has been reported that plerixafor combined with G-CSF may mobilize more primitive 
CD34+CD38- stem cells in MM patients (Fruehauf et al. 2009, Taubert et al. 2011). As discussed 
earlier in Chapter 2.5.2., these primitive stem cells have been shown to have a high self-renewal 
potential and the amount of infused CD34+CD38- cells may correlate with engraftment after 
ASCT. 
In NHL patients (study IV), plerixafor significantly increased both the proportion and the 
number of the most primitive stem cells (CD34+CD133+CD38-) in the stem cell graft in poorly 
mobilizing NHL patients treated with chemomobilization when compared to control group 
patients. This result corroborates the findings from a prior study by Fruehauf et al. (Fruehauf et 
al. 2009) in patients mobilized without chemotherapy. In patients with MM (study V) the results 
were similar as the proportion of the most primitive cells was significantly higher in plerixafor-
treated patients than in the control group. In MM patients, the absolute number of the most 
primitive cells did not differ between the groups. This was possibly due to the small number of 
patients, because the median proportions of primitive stem cells were significantly higher in 
plerixafor-treated patients. The results in study V are also in line with previously published 
results in MM patients mobilized without chemotherapy (Fruehauf et al. 2009, Taubert et al. 
2011). Taken together, these observations suggest that plerixafor may increase mobilization of 
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more primitive CD34+ cell subclasses both in NHL and MM patients, regardless of whether it is 
combined with G-CSF or with chemomobilization. However, short and long-term engraftment 
was similar between the groups in both studies after ASCT. Furthermore, the possible 
relationship between graft composition and engraftment cannot be fully assessed as only the 
first graft was analyzed in detail even though many patients received grafts collected with two 
or even three aphereses. 
The clinical relevance of the most primitive stem cells is at present unclear. Further studies 
are needed regarding the importance of more primitive stem cells in ASCT (Zubair et al. 2006). 
6.6. VIABILITY OF GRAFT CELLS 
7-AAD staining was used to evaluate the number of dead cells by flow cytometry. There were 
no significant differences in the amount of either dead CD34+ cells or lymphoid cells after 
freezing between the different mobilization groups among NHL or MM patients. In MM 
patients the proportion of dead lymphoid cells was higher in cyclophosphamide-treated 
patients, but perhaps due to the low numbers and high variability, no statistical significance 
was observed. These observations suggest that plerixafor-mobilized grafts have viability 
characteristics similar to G-CSF or chemomobilized grafts if freezing times range from a few 
months to about a year.  
Taking into account the relatively wide use of plerixafor in stem cell mobilization for ASCT, 
more refined characterization of CD34+ cells, including gene-expression profiling (Fruehauf et 
al. 2006, Donahue et al. 2009) and functional assays of various lymphocyte subsets 
(Schwartzberg et al. 2009), are also warranted. 
6.7. ENGRAFTMENT AND OUTCOME AFTER ASCT 
Plerixafor added to G-CSF resulted in superior mobilization of CD34+ cells compared to G-CSF 
alone in randomized studies and was associated with equal engraftment and outcome at one 
year post-transplant (DiPersio et al. 2009a, DiPersio et al. 2009b). In poor mobilizers the effects 
of plerixafor on long-term outcomes are less well established, and only small patient series have 
been published (Moreb el al. 2011, Alexander et al. 2011). Specifically, there are no published 
data available about long-term outcome after ASCT in poorly mobilizing NHL patients treated 
with chemomobilization plus plerixafor. 
The number of patients included in study VI (n=89) was larger than in any previous study 
investigating engraftment and long-term outcome after ASCT in NHL patients treated with 
chemomobilization and plerixafor. The patient groups were heterogeneous in terms of 
histology (patients in the plerixafor group more commonly had aggressive histology) and 
disease status at transplant (the plerixafor group included more relapsed patients). Therefore, it 
is likely that many patients in the plerixafor group had poorer long-term prognosis than 
patients in the control group.  
In study VI, the collected CD34+ cell dose was, not unexpectedly, higher in the control group 
than in the study group, which consisted of poor mobilizers. Yet, hematopoietic recovery was 
similar between the groups during the first year after ASCT. Infectious complications post-
transplant were also similar between the groups. Higher numbers of CD34+ cells in the graft 
have been linked with more rapid hematopoietic recovery and with better survival after ASCT 
in some studies as discussed earlier in Chapter 2.5.2. These observations in study VI may 
indicate that also factors other than solely CD34+ cell dose influence hematopoietic and immune 
recovery post-transplant. It is possible that these mobilization-related changes (e.g. changes in 
the cell composition of the graft) may explain similar outcomes between the groups. Absolute 
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lymphocyte count (ALC) on day +15, which has been found to be important for progression-free 
and overall survival in some retrospective studies (Porrata et al. 2001, Gordan et al. 2003), was 
not assessed in study VI. Taken together, these observations suggest that the quality of grafts 
collected with plerixafor is at least equal to the grafts collected without it, although prospective 
studies are needed to assess e.g. the tempo of immunorecovery after ASCT. As previously 
mentioned, this will be an important topic of the ongoing GOA study (Jantunen et al. 2013b). 
Another interesting issue in regard to the use of plerixafor for stem cell mobilization is the 
question of possible tumor cell mobilization.  Previous studies have not observed higher tumor 
cell mobilization in patients mobilized with G-CSF plus plerixafor (DiPersio et al. 2009, 
Fruehauf et al. 2010). When patients are treated with cytotoxic chemomobilization, tumor cell 
contamination has been reported to be similar when compared to G-CSF based mobilization 
(López-Pérez et al. 2000, Narayanasami et al. 2001). Possible contamination was not measured 
in any of the studies included in this thesis, but no increase in the risk of relapse was observed 
in plerixafor-treated patients, suggesting no excessive mobilization of tumor cells. 
The main conclusion from study VI was that the use of plerixafor to enhance blood stem cell 
mobilization in NHL patients appears to be associated with similar early and long-term 
engraftment as well as equal post-transplant outcomes. However, due to the retrospective 
nature, these preliminary observations must be confirmed in a prospective study setting.  
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7 Conclusions 
The main findings and conclusions of this series of studies were: 
 
 
 
I A significant proportion of NHL patients were found to be hard to mobilize with 
chemomobilization. The mobilization kinectics of these patients differ from 
standard mobilizers. An algorithm to optimize plerixafor use was developed to be 
prospectively validated. 
 
II Plerixafor combined to chemomobilization enhanced the yield of CD34+ cells in 
poorly mobilizing NHL patients. In addition, plerixafor increased the amount of 
leukocytes, neutrophils, lymphocytes, eosinophils and monocytes in the peripheral 
blood at the time of apheresis. 
 
III Plerixafor combined with chemomobilization in poorly mobilizing NHL patients 
seems to mobilize more T cells, helper T subsets, suppressor T subsets, and NK cells 
than chemomobilization alone. Use of plerixafor results in similar engraftment and 
outcome after ASCT compared to standard mobilizers. 
 
IV Plerixafor added to chemomobilization in poorly mobilizing NHL patients 
mobilizes more primitive CD34+ cells than chemomobilization alone. 
 
V Plerixafor combined with chemomobilization or G-CSF in poorly mobilizing MM 
patients increases the proportion of more primitive stem cells in the grafts. In 
addition, plerixafor may increase the amount of certain lymphocyte populations in 
stem cell grafts. 
 
VI Plerixafor combined with chemomobilization in poorly mobilizing patients with 
NHL results in rapid and long-term engraftment, and the outcome after ASCT is 
similar to standard mobilizers. 
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8 Future Perspectives 
At the moment, the major factor limiting the use of plerixafor for stem cell mobilization in 
autologous transplantation is its substantially higher price. Therefore, more sophisticated 
methods are needed to optimize the use of plerixafor in clinical practice and, on the other hand, 
to recognize patients who do not benefit from it. These aspects should be assessed in 
prospective studies with larger patient numbers. As the most effective combination for 
mobilizing stem cells is probably chemomobilization combined with plerixafor and many 
transplant centers still mobilize patients with chemomobilization, more data and algorithms to 
guide plerixafor use are warranted. Future studies should also include cost-benefit analysis that 
covers the costs of the entire mobilization and collection process. Furthermore, uniform and 
internationally accepted definitions for poor and inadequate mobilization should be created 
and put into practice.  
To evaluate the potential clinical impact of graft cellular content on patient outcomes 
including late post-transplant complications and risk of relapse, larger prospective studies and 
longer follow-up are needed. The effects of plerixafor on the cellular content of the graft should 
be evaluated in larger patient series and compared with traditional mobilization regimens. The 
possible link between graft cellular content, speed and tempo of engraftment including immune 
recovery post-ASCT and long-term outcome should also be studied. Some of these aspects will 
be studied in the ongoing GOA study in Finland (Jantunen et al. 2013b) and in the prospective 
phase II study of the Finnish Myeloma Group (FMG-MM02). In addition, gene expression 
profiling (Fruehauf et al. 2006, Donahue et al. 2009), more detailed phenotypic and functional 
studies of CD34+ cells as well as various functional aspects of lymphocyte activation (e.g. 
signaling lymphocyte activation molecules) (Schwartzberg et al. 2009) are needed. Also the 
possible mobilization of tumor cells and its clinical impact should be assessed.  
Because there will be patients intended for ASCT who fail mobilization even with plerixafor, 
new mobilizing agents are needed. Some molecules (e.g. POL6326) have entered early phase 
clinical trials (Rettig et al. 2012). As some of them will become commercially available, different 
mobilization methods should be compared in regard to safety, efficacy, graft composition, and 
possible impact on short- and long-term outcomes post-transplant. 
The first reports of chemosensitization with plerixafor in patients with acute leukemia have 
been published (Nervi et al. 2009, Uy et al. 2012). It remains to be seen whether this will be 
possible in MM or NHL patients. This would be especially interesting in patients with primarily 
refractory diseases or in patients with a high risk of the relapse. Promising preliminary studies 
in this topic have been published (Azab et al. 2009). Similar observations with solid tumors have 
also been reported (Domanska et al. 2012, Heckmann et al. 2013). However, more studies are 
urgently needed to assess the clinical utility of this treatment modality.  
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Autologous stem cell transplantation 
(ASCT) has an established role as a 
treatment modality for hematological 
malignancies. Stem cells for ASCT 
are almost invariably collected from 
peripheral blood after mobilization 
therapy. Plerixafor, a CXCR4 
antagonist, is the latest addition to 
stem cell mobilization and may be 
used in patients who mobilize poorly 
otherwise. This series of studies 
provides additional information to 
support the use of plerixafor.
